var title_f4_11_4272="Inflatable implant PI";
var content_f4_11_4272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflatable implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With an inflatable implant, erection is produced by squeezing a small pump (a) implanted in the scrotum. The pump causes fluid to flow from a reservoir (b) residing in the lower pelvis to two cylinders (c) residing in the penis. The cylinders expand to create the erection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4272=[""].join("\n");
var outline_f4_11_4272=null;
var title_f4_11_4273="2D TTE short axis LA appendage";
var content_f4_11_4273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1244px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/88545/2D_TTE_short_axis_LA_movie.mp4?title=2D+TTE+short+axis+LA+appendage\" style=\"width:528px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the aortic valve showing the left atrial (LA) appendage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left atrial appendage is seen on the right.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium; LAA: left atrial appendage; AoV: aortic valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4273=[""].join("\n");
var outline_f4_11_4273=null;
var title_f4_11_4274="First trimes nuchal lucency";
var content_f4_11_4274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester nuchal lucency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First trimester fetus. Nuchal translucency is the lucent zone at the posterior fetal neck observed sonographically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beryl R Benacerraf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4274=[""].join("\n");
var outline_f4_11_4274=null;
var title_f4_11_4275="Patient information: Asthma in adults (The Basics)";
var content_f4_11_4275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15343\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"         Asthma and its treatment",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43186\">",
"         Patient information: Breathing tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/20/14660\">",
"         Patient information: Asthma and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/25/29075\">",
"         Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/63/39925\">",
"         Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/26/1442\">",
"         Patient information: Exercise-induced asthma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/6/31841\">",
"         Patient information: How to use a peak flow meter (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/25/31124\">",
"         Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Asthma in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/asthma-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H44585039\">",
"      <span class=\"h1\">",
"       What is asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is a condition that can make it hard to breathe. Asthma does not always cause symptoms. But when symptoms occur, they can be scary. Asthma attacks happen when the airways in the lungs become narrow and inflamed (",
"      <a class=\"graphic graphic_figure graphicRef65956 \" href=\"UTD.htm?0/52/837\">",
"       figure 1",
"      </a>",
"      ). Asthma can run in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585046\">",
"      <span class=\"h1\">",
"       What are the symptoms of asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wheezing or noisy breathing",
"       </li>",
"       <li>",
"        Coughing",
"       </li>",
"       <li>",
"        A tight feeling in the chest",
"       </li>",
"       <li>",
"        Shortness of breath",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms can happen each day, each week, or less often. Symptoms can range from mild to severe. Although it is rare, an episode of asthma can sometimes even lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585053\">",
"      <span class=\"h1\">",
"       Is there a test for asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will ask you about your symptoms and have you do a breathing test to see how your lungs are working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585060\">",
"      <span class=\"h1\">",
"       How is asthma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is treated with different types of medicines. The medicines can be inhalers, liquids, or pills. Your doctor will prescribe medicine based on how often you have symptoms and how serious your symptoms are. Asthma medicines work in one of two ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Quick-relief medicines",
"        </strong>",
"        stop symptoms quickly &mdash; in 5 to 15 minutes. Almost everyone with asthma has a quick-relief inhaler that they carry with them. People use these medicines whenever they have asthma symptoms. Most people need these medicines 1 or 2 times a week&mdash;or less often. But when asthma symptoms get worse, more doses may be needed. Some people can feel shaky after taking these medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Long-term controller medicines",
"        </strong>",
"        control asthma and prevent future symptoms. People with frequent asthma symptoms take these one or two times each day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is very important that you take all the medicines the doctor prescribes, exactly how you are supposed to take them. You might have to take medicines a few times a day. You might not feel a medicine working, but that does not mean it is not helping you.",
"     </p>",
"     <p>",
"      Asthma that is not treated with the right medicines can damage the lungs. Plus, not taking your medicines correctly can cause symptoms to get worse and even require a trip to the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585067\">",
"      <span class=\"h1\">",
"       What is an asthma action plan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An asthma action plan is a list of instructions that tell you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Which medicines to use each day at home",
"       </li>",
"       <li>",
"        Which medicines to take if your symptoms get worse",
"       </li>",
"       <li>",
"        When to get help or call 9-1-1",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have frequent or severe asthma symptoms, your doctor might suggest that you have an asthma action plan. If so, you and your doctor will work together to make one. As part of your action plan, you may need to use something called a &ldquo;peak flow meter.&rdquo; Breathing into this device will show how your lungs are working. Your doctor will show you the right way to use your inhaler and peak flow meter.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585074\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes.",
"      <strong>",
"       Call 9-1-1 for an ambulance",
"      </strong>",
"      if you have a severe asthma attack and your symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get worse",
"       </li>",
"       <li>",
"        Do not improve after using a quick-relief medicine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you need asthma medicine every day, you should see your doctor every 6 months or more often.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585081\">",
"      <span class=\"h1\">",
"       Can asthma symptoms be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can help prevent your asthma symptoms. You can stay away from things that cause your symptoms or make them worse. Doctors call these &ldquo;triggers.&rdquo; If you know what your triggers are, avoid them as much as possible. Some common triggers include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dust",
"       </li>",
"       <li>",
"        Mold",
"       </li>",
"       <li>",
"        Animals, such as dogs and cats",
"       </li>",
"       <li>",
"        Pollen and plants",
"       </li>",
"       <li>",
"        Cigarette smoke",
"       </li>",
"       <li>",
"        Getting sick with a cold or flu (that&rsquo;s why it&rsquo;s important to get a flu shot)",
"       </li>",
"       <li>",
"        Exercise",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can&rsquo;t avoid certain triggers, talk with your doctor about what you can do. For example, exercise can be good for people with asthma. But you may need to take an extra dose of your quick-relief inhaler medicine before you exercise.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585088\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor about how to control your asthma. Keeping your asthma well-controlled is important for the health of your baby. Most asthma medicines are safe to take if you are pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H44585095\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       Patient information: Breathing tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"       Patient information: Asthma and pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"       Patient information: Exercise-induced asthma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       Patient information: How to use a peak flow meter (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/11/4275?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15343 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4275=[""].join("\n");
var outline_f4_11_4275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585039\">",
"      What is asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585046\">",
"      What are the symptoms of asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585053\">",
"      Is there a test for asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585060\">",
"      How is asthma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585067\">",
"      What is an asthma action plan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585074\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585081\">",
"      Can asthma symptoms be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585088\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44585095\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"      Asthma and its treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=related_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=related_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4276="Lymphomatoid gran CT I";
var content_f4_11_4276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    35-year-old man who presented with cerebral symptoms with enhancing brain mass on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image shows well-defined and poorly defined nodules throughout lung. Most nodules are smaller than 1 cm. Nodules are located along bronchovascular structures or interlobular septa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4276=[""].join("\n");
var outline_f4_11_4276=null;
var title_f4_11_4277="Nonpharmacologic management of Parkinson disease";
var content_f4_11_4277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonpharmacologic management of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4277/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4277/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4277/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4277/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4277/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4277/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4277/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinson disease (PD) is a chronic disorder that requires broad-based management including patient and family education, support group services, general wellness maintenance, exercise, and nutrition. Treatment of PD can be divided into nonpharmacologic, pharmacologic, and surgical therapy. A useful algorithm for the management of PD has been published by the American Academy of Neurology (AAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the nonpharmacologic management of PD. The pharmacologic treatment of PD and the treatment of comorbid problems associated with it are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"     \"Management of comorbid problems associated with Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prospect of having a chronic and progressive neurologic disease is frightening. Many individuals are familiar with Parkinson disease (PD) and may even have had first-hand acquaintance with its disabling effects in an affected family member or friend. Education is essential in order to provide the patient and family with some understanding and control over the disorder.",
"   </p>",
"   <p>",
"    However, caution should be exercised in newly diagnosed patients with mild symptoms and an uncertain future with regard to progression; early overexposure to potentially disturbing material may be counterproductive. Focused education surrounding particular symptoms may be more effective and is available through books and other materials (see",
"    <a class=\"local\" href=\"#H20474307\">",
"     'Information for patients'",
"    </a>",
"    below) written for the lay audience, through national and regional Parkinson disease organizations (",
"    <a class=\"graphic graphic_table graphicRef66006 \" href=\"UTD.htm?3/24/3469\">",
"     table 1",
"    </a>",
"    ), which publish educational pamphlets and organize symposia for patients and families, and through the internet. A useful online information resource is the",
"    <a class=\"external\" href=\"file://www.wemove.org/\">",
"     We Move",
"    </a>",
"    organization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emotional and psychologic needs of the patient with PD and family should be addressed. Normal reactions of anger, depression, anxiety, and social and economic concerns often begin with the onset of the disease and evolve as it progresses. Support for the caregiver is particularly important as he or she learns to cope with the increasing needs of the spouse or parent, or more rarely, a son or daughter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/2\">",
"     2",
"    </a>",
"    ]. Support groups are especially valuable for allowing interactions with other patients or families with similar experiences and for providing access to useful educational information [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with early PD, referral to another affected patient or family may be less overwhelming than a large support group composed of patients with advanced disease. Young-onset PD groups also have been formed in some locales, and a young-onset PD handbook is available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/4\">",
"     4",
"    </a>",
"    ]. There are also some national support organizations, several of which have local chapters (",
"    <a class=\"graphic graphic_table graphicRef66006 \" href=\"UTD.htm?3/24/3469\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Referral of the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family to a psychologist or psychiatric social worker experienced in dealing with chronic illness may be appropriate in some cases. In other instances, referral for legal, financial, or occupational counseling is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXERCISE AND PHYSICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise promotes a feeling of physical and mental well-being; it is especially valuable due to the chronic nature of PD and its associated progressive motor limitations. Exercise may not slow the progression of akinesia, rigidity, or gait disturbance, but it can alleviate some secondary orthopedic effects of rigidity and flexed posture such as shoulder, hip, and back pain, and it may also improve function in some motor tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As examples, mounting evidence suggests that regular aerobic exercise has a positive impact on PD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In addition, a randomized controlled trial of 195 subjects with mild to moderate PD found that a six month program of twice-weekly tai chi training was superior to resistance training and stretching for improvement in measurements of postural stability, stride length, and functional reach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/9\">",
"     9",
"    </a>",
"    ]. There were fewer of self-reported falls at six months for the tai chi group compared with the resistance training and stretching groups (62 versus 133 versus 186), and the difference was statistically significant for the comparison with the stretching group.",
"   </p>",
"   <p>",
"    Thus, exercises to improve balance, flexibility and strength should be emphasized. Brisk walks, tai chi, swimming, and water aerobic exercises appear to be particularly useful. Referral to a physical therapist or exercise group may be a good way to get patients started in such activities.",
"   </p>",
"   <p>",
"    A practice parameter from the American Academy of Neurology (AAN) issued in 2006 concluded that various physical therapy modalities are probably effective in improving functional outcome for patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"     6",
"    </a>",
"    ]. These modalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multidisciplinary rehabilitation with standard physical and occupational therapy components [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treadmill training with body weight support [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Balance training and high-intensity resistance training [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cued exercises with visual (mirror), auditory (metronome), and tactile feedback [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Active music therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006 AAN review found that the magnitude of the observed functional improvement with these interventions was small and not sustained after therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, a 2012 systematic review observed that most of the benefits with physical therapy for patients with PD were small [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Nevertheless, many patients gain lasting confidence and a sense of control over one aspect of the disease, especially if they have never engaged in physical activity in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPEECH THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysarthria and hypophonia are common manifestations of PD. The practice parameter from the American Academy of Neurology (AAN) issued in 2006 concluded that speech therapy for patients with PD may be helpful in improving speech volume [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This conclusion was based on two small trials that compared speech therapy with no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. One employed speech therapy emphasizing prosodic features of pitch and volume reinforced with visual feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/18\">",
"     18",
"    </a>",
"    ], while the other employed therapy aimed solely at maximizing phonatory effort and loudness (the Lee Silverman Voice Treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/19\">",
"     19",
"    </a>",
"    ]. Both of these methods were found to be possibly effective by the AAN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"     6",
"    </a>",
"    ]. A 2012 systematic review evaluated the same trials and concluded that although many of the outcome measures were significantly improved with therapy, the small patient numbers (n = 41), methodologic limitations of the trials, and possible publication bias preclude firm conclusions regarding the efficacy of speech and language therapy for PD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients with chronic illness are at risk for poor nutrition and weight loss. Prompt recognition and management of this problem is important to avoid loss of bone and muscle mass. No specific diet influences the course of PD, although certain recommendations can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high fiber diet and adequate hydration help manage the constipation of PD.",
"     </li>",
"     <li>",
"      Large, high-fat meals that slow gastric emptying and interfere with medication absorption should be avoided.",
"     </li>",
"     <li>",
"      Dietary protein restriction is not necessary except in some patients with advanced disease and motor fluctuations in whom competition with other amino acids interferes with L-dopa absorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=see_link&amp;anchor=H10#H10\">",
"       \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Unpredictable off periods'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=see_link&amp;anchor=H12#H12\">",
"       \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Failure of on-response'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence at this time that large doses of vitamin E or other antioxidants are useful in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=see_link\">",
"       \"Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84427557\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education is essential in order to provide the patient with Parkinson disease (PD) and family with some understanding and control over the disorder. In addition, the emotional and psychologic needs of the patient and family should be addressed. Support groups are a valuable resource (",
"      <a class=\"graphic graphic_table graphicRef66006 \" href=\"UTD.htm?3/24/3469\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Education'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular exercise and various physical therapy modalities appear to offer some benefit for improving function in patients with PD. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Exercise and physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysarthria and hypophonia are common manifestations of PD. Speech therapy may be helpful in improving speech volume and maintaining voice quality. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Speech therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific diet influences the course of PD, but a high fiber diet and adequate hydration can help to reduce the constipation of PD, while large, high-fat meals that slow gastric emptying and interfere with medication absorption should be avoided. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/1\">",
"      Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/2\">",
"      Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord 1998; 13:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/3\">",
"      Mittelman MS, Ferris SH, Shulman E, et al. A comprehensive support program: effect on depression in spouse-caregivers of AD patients. Gerontologist 1995; 35:792.",
"     </a>",
"    </li>",
"    <li>",
"     Young Parkinson's Handbook, Mark MH, Sage JI (Eds), The American Parkinson Disease Association, Inc, New York 2000. www.stlapda.org/content/pdfs/Young%20Parkinson%20Handbook.pdf (Accessed on February 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/5\">",
"      Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology 1994; 44:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/6\">",
"      Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/7\">",
"      Ridgel AL, Vitek JL, Alberts JL. Forced, not voluntary, exercise improves motor function in Parkinson's disease patients. Neurorehabil Neural Repair 2009; 23:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/8\">",
"      Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 2011; 77:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/9\">",
"      Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012; 366:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/10\">",
"      Wade DT, Gage H, Owen C, et al. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2003; 74:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/11\">",
"      Miyai I, Fujimoto Y, Ueda Y, et al. Treadmill training with body weight support: its effect on Parkinson's disease. Arch Phys Med Rehabil 2000; 81:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/12\">",
"      Miyai I, Fujimoto Y, Yamamoto H, et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2002; 83:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/13\">",
"      Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003; 84:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/14\">",
"      Marchese R, Diverio M, Zucchi F, et al. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 2000; 15:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/15\">",
"      Pacchetti C, Mancini F, Aglieri R, et al. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psychosom Med 2000; 62:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/16\">",
"      Herd CP, Tomlinson CL, Deane KH, et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease. Cochrane Database Syst Rev 2012; 8:CD002812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/17\">",
"      Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ 2012; 345:e5004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/18\">",
"      Johnson JA, Pring TR. Speech therapy and Parkinson's disease: a review and further data. Br J Disord Commun 1990; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/19\">",
"      Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4277/abstract/20\">",
"      Herd CP, Tomlinson CL, Deane KHO, et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease. Cochrane Database Syst Rev 2012; :CD002812.",
"     </a>",
"    </li>",
"    <li>",
"     Nutt, JG, Carter, JH. Dietary issues in the treatment of Parkinson's disease. In: Therapy of Parkinson's Disease, Koller, WC, Paulson, G (Eds), Marcel Dekker, New York, 1990. p.531.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4899 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4277=[""].join("\n");
var outline_f4_11_4277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H84427557\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXERCISE AND PHYSICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPEECH THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84427557\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/24/3469\" title=\"table 1\">",
"      Parkinson disease organizations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=related_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=related_link\">",
"      Motor fluctuations and dyskinesia in Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4278="Varicella-zoster infection in the newborn";
var content_f4_11_4278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Varicella-zoster infection in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Michael E Speer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4278/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4278/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) is the virus responsible for varicella (chickenpox) and herpes zoster (\"shingles\"). VZV is a member of the herpesvirus family, along with herpes simplex virus (HSV) types 1 and 2, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus (HHV) -6, -7, and -8.",
"   </p>",
"   <p>",
"    Varicella usually is a mild, self-limited illness in healthy children. Rarely, varicella affects the pregnant or postpartum woman, causing problems for the fetus or newborn. Nosocomial acquisition of VZV also can occur in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONGENITAL VARICELLA SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of congenital varicella syndrome occur in infants whose mothers were infected between 8 and 20 weeks gestation. However, the overall risk of infection is quite small compared to numerous other viruses acquired during pregnancy. The risk appears to be approximately 2 percent if the infection occurs before 20 weeks and less than 1 percent if it occurs before 13 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Intrauterine growth restriction commonly occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristic findings of affected infants include some or all of the following in order of the frequency of occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cicatricial skin lesions, which may be depressed and pigmented in a dermatomal distribution.",
"     </li>",
"     <li>",
"      Ocular defects, such as cataracts, chorioretinitis, Horner syndrome, microophthalmos, and nystagmus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"       \"Cataract in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limb abnormalities, which often include hypoplasia of bone and muscle.",
"     </li>",
"     <li>",
"      Central nervous system abnormalities, such as cortical atrophy, seizures, and intellectual disability (mental retardation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEONATAL VARICELLA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal varicella is a serious illness associated with a mortality rate up to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/4\">",
"     4",
"    </a>",
"    ]. Newborns born to mothers who are exposed to VZV or have clinical disease manifestations within two weeks of delivery are at the greatest risk for infection. Nosocomial acquisition of VZV also can occur.",
"   </p>",
"   <p>",
"    The risk of infection and the case fatality rate are significantly increased when symptoms of maternal infection occur less than five days prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/5\">",
"     5",
"    </a>",
"    ]. This interval allows insufficient time for the development of maternal IgG and passive transfer of antibody protection to the fetus. Postnatally acquired varicella that occurs between 10 and 28 days after birth usually is mild [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/6\">",
"     6",
"    </a>",
"    ]. However, because of their relative immunologic immaturity, newborns are at greater risk for acquiring severe disease than are older infants or children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature infants are at increased risk for nosocomial acquisition of VZV compared to infants born at term because active transfer of maternal IgG antibodies occurs primarily during the third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/8\">",
"     8",
"    </a>",
"    ]. Postnatal age also is a risk factor because antibody levels decline with age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one report of VZV exposure in a Neonatal Intensive Care Unit (NICU), seronegativity occurred frequently in infants older than two months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of neonatal varicella is variable, ranging from a mild illness resembling chickenpox in older children to a disseminated infection similar to manifestations seen in immunocompromised hosts. Fever may develop within the first days after birth, followed by a vesicular eruption. In mild cases, the lesions heal within 7 to 10 days. However, disseminated disease may ensue, with varicella pneumonia, hepatitis, and meningoencephalitis being the most common visceral manifestations. Reports of neonatal herpes zoster in babies born to mothers with varicella during pregnancy are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Administration of varicella-zoster immune globulin (ie, VariZIG) within one day of age to infants born to women with active varicella infection at delivery may ameliorate neonatal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of varicella usually is made clinically based upon the characteristic appearance of skin lesions. VZV may be cultured from vesicular fluid, but the virus takes several weeks to grow, unlike HSV, which can be recovered in 48 to 72 hours. Other rapid diagnostic studies include direct fluorescent antigen (DFA) and polymerase chain reaction (PCR). PCR is a highly sensitive and specific test that detects VZV from either vesicular swabs or scrappings, scabs from crusted lesions, tissue from biopsy samples, and cerebral spinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic tests may help to document acute infection in confusing cases or indicate immunity. IgM antibody may be detected as soon as three days after VZV symptoms appear, and IgG may be detected as early as seven days after varicella symptoms appear. Other diagnostic tests include fluorescent anti-membrane antibody (FAMA), latex agglutination (LA), enzyme-linked immunosorbent assay (ELISA), and complement-enhanced neutralization, are available. All of these tests are more sensitive than is the older complement fixation (CF) assay. Although PCR is the most sensitive, LA and DFA provide the most rapid results. Prenatal diagnosis of fetal varicella infection is possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of newborns who are exposed to VZV by maternal infection or contact with affected individuals includes isolation and postexposure prophylaxis. The specific intervention depends upon the timing of exposure, the mother's serologic status, and gestational age. Varicella vaccination, which is used for prevention in older children and adults, has not been tested for this purpose in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Varicella-zoster immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster immune globulin (VZIG) was discontinued in the United States in 2005 and has been replaced by VariZIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     VariZIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;VariZIG is a purified human immune globulin preparation made from plasma containing high levels of anti-varicella antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link&amp;anchor=H11#H11\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\", section on 'VariZIG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postexposure prophylaxis has been shown to either prevent varicella in exposed neonates, ameliorate the course, or delay the disease in patients in whom the infection was not fully prevented [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Advisory Committee on Immunization Practices (ACIP) recommends administration of VariZIG to newborns who have had a significant exposure to VZV that are the same circumstances used in the past for VZIG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates whose mothers have signs and symptoms of varicella around the time of delivery (five days before or two days after).",
"     </li>",
"     <li>",
"      Premature infants born at &gt;28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have signs of immunity.",
"     </li>",
"     <li>",
"      Premature infants born at &lt;28 weeks of gestation or who weigh &lt;1000 grams at birth and were exposed during the neonatal period, regardless of maternal history of varicella or vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VariZIG should be administered within 96 hours because its efficacy after this time interval is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/14\">",
"     14",
"    </a>",
"    ]. The recommended dose is 125 units (1 vial) intramuscularly. VariZIG is lyophilized and must be reconstituted for intramuscular administration.",
"   </p>",
"   <p>",
"    In the United States, VariZIG is available under an Investigational New Drug Application Expanded Access protocol and may be obtained by contacting the distributor of this product, FFF Enterprises, at 800-843-7477 and faxing a completed release form. The release form can be accessed from the manufacturer's website:",
"    <span class=\"nowrap\">",
"     (file://www.fffenterprises.com/Products/VariZIG.aspx,",
"    </span>",
"    last accessed December 8, 2011) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If VariZIG cannot be administered within 96 hours of exposure, then intravenous immunoglobulin (IVIG) should be considered. If IVIG is unavailable, some experts would recommend prophylaxis with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link&amp;anchor=H9#H9\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\", section on 'Passive immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation for the mother and infant depends upon whether there is active disease or the timing of exposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active disease &mdash; A mother with active VZV lesions must be isolated. The infant is isolated from the mother until she is not infectious. If the onset of maternal disease occurred within 5 days before or 2 days after delivery, the infant should be treated with VariZIG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any infant who develops varicella in the nursery or NICU is also isolated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active disease 21 days before delivery &mdash; A mother who has active varicella within 21 days of delivery that resolves before hospitalization does not need to be isolated. However, the newborn should stay in the mother's room and be isolated from other infants. The infant should have passively acquired maternal antibody and therefore does not need to receive varicella-zoster immune globulin.",
"     </li>",
"     <li>",
"      Maternal exposure 6 to 21 days before hospitalization &mdash; A seronegative mother exposed to VZV 6 to 21 days before hospital admission should be isolated from other patients and the nursery because she may develop varicella while hospitalized. This calculation takes into account the incubation period of varicella, which is 8 to 21 days plus a possible period of infectivity three days before lesions appear. Her infant, if born at term, should be isolated with the mother. The mother and infant should be cared for only by staff with immunity to VZV. Both should be discharged as soon as possible.",
"     </li>",
"     <li>",
"      Maternal exposure within 6 days of hospitalization &mdash; If a seronegative mother was exposed within 6 days of admission and discharged before 48 hours, isolation is not needed because varicella would not be expected to develop during the hospital stay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nursery exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant who develops varicella in the nursery or NICU should be isolated. The more common situation is nursery exposure by a visitor or hospital worker who is infectious. In the newborn nursery, exposed infants typically are discharged before they would be infectious.",
"   </p>",
"   <p>",
"    Postnatally acquired varicella in infants older than 10 days of age usually is mild. Thus, some clinicians favor providing routine newborn care without administration of VariZIG or determination of maternal immune status. However, administration of VariZIG may be considered for an infant exposed during the first month after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/7\">",
"     7",
"    </a>",
"    ]. In this case, one approach is to give VariZIG only if maternal serology is negative.",
"   </p>",
"   <p>",
"    Isolation may be required for the rare infant who remains hospitalized longer than eight days and whose mother is seronegative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     NICU exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed infants in the NICU usually are cohorted. They are isolated from new patients admitted between 8 and 21 days after exposure. VariZIG should be given to all NICU patients with seronegative mothers and to all preterm infants &lt;28 weeks gestation or &le;1000g birth weight regardless of maternal immune status [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Infants who received VariZIG should be isolated from new patients for 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     Acyclovir",
"    </a>",
"    reduces the risk of mortality in severe varicella. Newborns with severe infection should be treated with acyclovir (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in 3 divided doses IV) for 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. To be effective, antiviral treatment must be started as soon as possible after the onset of symptoms because most viral replication has stopped by 72 hours after appearance of the rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fever control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever control rarely is needed in varicella because temperature elevations usually are mild. The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because of the increased risk of developing Reye syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/19\">",
"     19",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may prolong the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/20\">",
"     20",
"    </a>",
"    ]. Nonsteroidal antiinflammatory agents have not been recommended in this condition because of a proposed association with necrotizing group A streptococcal infections, although this association was not supported by a case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/21\">",
"     21",
"    </a>",
"    ]. If temperature elevation persists, the patient should be evaluated for secondary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether VZV is secreted in human milk is uncertain, although VZV DNA has been detected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/22\">",
"     22",
"    </a>",
"    ]. Breastfeeding is encouraged in newborns exposed to or infected with varicella because antibody in breast milk may be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4278/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster viral (VZV) infection in the newborn is due to either vertical transmission from the mother during pregnancy or delivery, or acquired after birth from the environment or infected care providers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital varicella syndrome occurs in infants whose mothers are infected between 8 and 20 weeks gestation. Clinical manifestations vary and include Cicatricial skin lesions, ocular defects (eg, cataracts, chorioretinitis, Horner syndrome, microophthalmos, and nystagmus), and abnormalities of the limb (eg, hypoplasia of bone and muscle) and central nervous system (eg, cortical atrophy, seizures, and cognitive impairment). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Congenital varicella syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link&amp;anchor=H9#H9\">",
"       \"Varicella-zoster virus infection in pregnancy\", section on 'Clinical features of congenital varicella syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonatal varicella is a serious illness with a mortality rate as high as 30 percent.",
"     </li>",
"     <li>",
"      Neonates born to mothers with VZV infection, or who were exposed within two weeks of delivery are at high risk for neonatal varicella. The risk and severity of illness increases when maternal infection occurs less than five days prior to delivery because there is insufficient time for the development and transfer of maternal antibody. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Neonatal varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of neonatal varicella vary from a mild illness similar to chickenpox in older children to a disseminated disease involving the liver, lung, and central nervous system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of varicella usually is made clinically based upon the characteristic appearance of skin lesions. VZV infection is confirmed by detection of the virus in vesicular fluid culture, or by direct fluorescent antigen and polymerase chain reaction (PCR) in vesicular scrappings, swabs, and, for PCR, cerebral spinal fluid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postexposure prophylaxis with VariZIG is recommended for infants born to symptomatic mothers around the time of delivery, preterm infants with gestational age (GA) &gt;28 weeks born to mothers without immunity and preterm infants &lt;28 weeks. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'VariZIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mothers with active disease or a history of exposure 6 to 21 days must be isolated from other patients including her infant. The newborn is isolated from the mother until she is no longer infectious. Any infant who develops varicella is isolated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Isolation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a 10-day course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 3 divided doses IV) to treat neonatal varicella. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acyclovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breastfeeding is encouraged in infants exposed to or infected with varicella. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/1\">",
"      Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/2\">",
"      Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548.",
"     </a>",
"    </li>",
"    <li>",
"     Gershon, AA. Chickenox, measles, and mumps. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, et al. (Eds), Elsevier Saunders, Philadelphia 2010. p.661.",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncbddd/pregnancy_gateway/infections-chickenpox.html (Accessed on October 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/5\">",
"      Meyers JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis 1974; 129:215.",
"     </a>",
"    </li>",
"    <li>",
"     Bailey, JE, Toltzis, P. Perinatal viral infections. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.841.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/7\">",
"      Prober CG, Gershon AA, Grose C, et al. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J 1990; 9:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/8\">",
"      Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 1999; 4:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/9\">",
"      Lipton SV, Brunell PA. Management of varicella exposure in a neonatal intensive care unit. JAMA 1989; 261:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/10\">",
"      Ng PC, Lyon DJ, Wong MY, et al. Varicella exposure in a neonatal intensive care unit: emergency management and control measures. J Hosp Infect 1996; 32:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/11\">",
"      David TJ, Williams ML. Herpes zoster in infancy. Scand J Infect Dis 1979; 11:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/12\">",
"      Dworsky M, Whitley R, Alford C. Herpes zoster in early infancy. Am J Dis Child 1980; 134:618.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella-Zoster infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/15\">",
"      Tebruegge M, Pantazidou A, Curtis N. Towards evidence based medicine for paediatricians. How effective is varicella-zoster immunoglobulin (VZIG) in preventing chickenpox in neonates following perinatal exposure? Arch Dis Child 2009; 94:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/16\">",
"      Heuchan AM, Isaacs D. The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases. Med J Aust 2001; 174:288.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antiviral drugs. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.840.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/18\">",
"      Kesson AM, Grimwood K, Burgess MA, et al. Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. J Paediatr Child Health 1996; 32:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/19\">",
"      Autret-Leca E, Jonville-B&eacute;ra AP, Llau ME, et al. Incidence of Reye's syndrome in France: a hospital-based survey. J Clin Epidemiol 2001; 54:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/20\">",
"      Doran TF, De Angelis C, Baumgardner RA, Mellits ED. Acetaminophen: more harm than good for chickenpox? J Pediatr 1989; 114:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/21\">",
"      Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001; 107:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/22\">",
"      Yoshida M, Yamagami N, Tezuka T, Hondo R. Case report: detection of varicella-zoster virus DNA in maternal breast milk. J Med Virol 1992; 38:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4278/abstract/23\">",
"      Grumach AS, Carmona RC, Lazarotti D, et al. Immunological factors in milk from Brazilian mothers delivering small-for-date term neonates. Acta Paediatr 1993; 82:284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4969 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-131D73BB27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4278=[""].join("\n");
var outline_f4_11_4278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONGENITAL VARICELLA SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEONATAL VARICELLA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Varicella-zoster immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - VariZIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nursery exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NICU exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fever control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4279="Management of hyperkalemia in children";
var content_f4_11_4279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hyperkalemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Michael J Somers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4279/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H635271753\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is typically defined as a serum or plasma potassium greater than 5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     (mmol/L).",
"    </span>",
"    Although children are less likely to develop hyperkalemia than adults, pediatric hyperkalemia is not an uncommon occurrence, and severe hyperkalemia (potassium level greater than 7.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     [mmol/L])",
"    </span>",
"    is a serious medical problem that needs immediate attention.",
"   </p>",
"   <p>",
"    The management of hyperkalemia in children is reviewed here. The etiology, clinical findings, diagnosis, and evaluation of pediatric hyperkalemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link\">",
"     \"Causes, diagnosis, and evaluation of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691997633\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia in children is caused by derangements of the hemostatic mechanisms that normally regulate potassium balance, which are the same as those that occur in adults. However, the most common cause of an elevated potassium level is pseudohyperkalemia, which is typically caused by a hemolyzed blood sample.",
"   </p>",
"   <p>",
"    It is generally due to one or a combination of the following mechanisms (",
"    <a class=\"graphic graphic_table graphicRef85965 \" href=\"UTD.htm?18/36/19020\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive increase in potassium intake",
"     </li>",
"     <li>",
"      Transcellular movement of intracellular potassium into the extracellular space (eg, rhabdomyolysis from crush injury or exercise, tumor lysis syndrome, massive transfusion, and metabolic acidosis)",
"     </li>",
"     <li>",
"      Decreased renal excretion of potassium (impaired effective arterial perfusion, renal dysfunction, or hypoaldosteronism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent hyperkalemia generally requires impaired urinary potassium excretion.",
"   </p>",
"   <p>",
"    The urgency of treatment of hyperkalemia varies with the cause and the presence or absence of the symptoms and signs associated with hyperkalemia. As an example, patients with marked tissue breakdown (eg, rhabdomyolysis, crush injury, tumor lysis syndrome) release large amounts of potassium from the cells, which can lead to rapid and substantial elevations in serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H266365934#H266365934\">",
"     \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most serious manifestations of hyperkalemia are cardiac conduction abnormalities and arrhythmias, which generally occur when the potassium concentration is &ge;7.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    with chronic hyperkalemia, or possibly at lower levels with an acute rise in serum potassium.",
"   </p>",
"   <p>",
"    The initial assessment and management of pediatric hyperkalemia includes the following and is summarized in a Table provided to facilitate emergent management (",
"    <a class=\"graphic graphic_table graphicRef85978 \" href=\"UTD.htm?27/41/28318\">",
"     table 2",
"    </a>",
"    ). There is good evidence for this approach, which is the same as that used in adult patients with hyperkalemia as the underlying principles are identical [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of hyperkalemia includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial acute management that rapidly counteracts the adverse cardiac effects of hyperkalemia in children with severe hyperkalemia, which is a potentially life-threatening condition",
"     </li>",
"     <li>",
"      Treatment of the underlying cause of hyperkalemia",
"     </li>",
"     <li>",
"      Removal of potassium",
"     </li>",
"     <li>",
"      Elimination or reduction of potassium intake for patients, especially those with persistent hyperkalemia due to impairment of urinary potassium excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270633\">",
"    <span class=\"h1\">",
"     RAPID THERAPY TO COUNTERACT CARDIAC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because hyperkalemia is a potentially life-threatening condition, initial acute management of elevated potassium takes precedence over any diagnostic evaluation. Acute rapid transient measures include stabilizing the cardiac membrane and shifting potassium from the extracellular space into the cells (",
"    <a class=\"graphic graphic_table graphicRef85978 \" href=\"UTD.htm?27/41/28318\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691998055\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;These measures are used for children in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a potassium level greater than 7.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Patients with a rapidly rising potassium level (eg, tumor lysis syndrome or major crush injury)",
"     </li>",
"     <li>",
"      Patients with significant electrocardiographic changes, such as widening of the QRS complex, loss of P waves, or arrhythmias thought to be caused by hyperkalemia, but not for isolated peaked T waves (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Hyperkalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958377#H85958377\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Cardiac conduction abnormalities'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691998062\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For these patients, the following management approach is recommended based on systematic review of the literature and clinical experience (",
"    <a class=\"graphic graphic_table graphicRef85978 \" href=\"UTD.htm?27/41/28318\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation that the patient is truly hyperkalemic, especially if the clinical setting makes the diagnosis of hyperkalemia unlikely (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H266365994#H266365994\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Pseudohyperkalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958478#H85958478\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      While awaiting confirmation of hyperkalemia, obtain an electrocardiogram (ECG). If there are signs indicative of conduction abnormalities, place the patient on a cardiac monitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958377#H85958377\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Cardiac conduction abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac membrane stabilization with a slow infusion of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      (10 percent solution) (see",
"      <a class=\"local\" href=\"#H635270648\">",
"       'Cardiac membrane stabilization'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Therapy to shift extracellular potassium into the cells (see",
"      <a class=\"local\" href=\"#H635270655\">",
"       'Therapies shifting potassium into intracellular space'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"       regular insulin",
"      </a>",
"      and glucose",
"     </li>",
"     <li>",
"      Inhaled beta-adrenergic agonists, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol (salbutamol)",
"      </a>",
"     </li>",
"     <li>",
"      It is uncertain how effective intravenous bicarbonate may be and it should",
"      <strong>",
"       not",
"      </strong>",
"      be the only intervention used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring the potassium levels one to two hours after initiation of therapy. In addition, a repeat ECG or serial ECGs should be performed to demonstrate resolution of hyperkalemia-associated cardiac conduction abnormalities or arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270648\">",
"    <span class=\"h3\">",
"     Cardiac membrane stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium directly antagonizes the hyperkalemia-induced depolarization of the resting cardiac membrane. Calcium therapy results in decreased membrane excitability and reduces the risk of developing cardiac conduction abnormalities and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/3\">",
"     3",
"    </a>",
"    ]. It should be given",
"    <strong>",
"     only",
"    </strong>",
"    for hyperkalemia with significant ECG findings (eg, widening of the QRS complex or loss of P waves, but",
"    <strong>",
"     not",
"    </strong>",
"    peaked T waves alone), severe arrhythmias thought to be caused by hyperkalemia, or in patients with a potassium level greater than 7.0",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of hyperkalemia in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    10 percent solution is given at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (maximum dose 20 mL [2 g]) by intravenous slow infusion over five minutes. Time to onset of action is immediate. This suggested dose is equivalent to a dose of elemental calcium 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mmol/kg;",
"    </span>",
"    maximum dose of 180 mg elemental calcium [4.5 mmol]).",
"   </p>",
"   <p>",
"    Although the protective effect of infused calcium is rapid in onset, its duration may be short-lived and further infusions may be necessary. Concomitant therapies that promote the shift of potassium into the intracellular space should also be initiated as quickly as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270655\">",
"    <span class=\"h3\">",
"     Therapies shifting potassium into intracellular space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following interventions shift potassium from the extracellular spaces to within the cell and are rapid in onset, but generally have limited duration (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled beta-adrenergic agonists &ndash; Because securing intravenous access in young children can be challenging, inhaled beta-adrenergic agonists are often a good initial option. Several case reports and series have demonstrated a decrease of serum potassium of 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      within an hour of administration [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/4\">",
"       4",
"      </a>",
"      ]. Such therapy has also been shown to be effective and safe in premature neonates, with one report demonstrating a 20-fold decrease in potassium levels after two nebulization treatments of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      compared with inhaled saline [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Beta-adrenergic agonists should be avoided in children manifesting any pre-existing cardiac arrhythmia, and children should be on a cardiac monitor during its administration. Tachycardia and tremors are common side effects but are usually short-lived.",
"      <br/>",
"      <br/>",
"      Dosing of albuterol is based on the child&rsquo;s weight as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonates: 0.4 mg in 2 mL of saline",
"     </li>",
"     <li>",
"      Infants and small children &lt;25.0 kg: 2.5 mg in 2 mL of saline",
"     </li>",
"     <li>",
"      Children between 25 and 50 kg: 5 mg in 2 mL of saline",
"     </li>",
"     <li>",
"      Older children and adolescents &gt;50 kg: 10 mg in 2 to 4 mL of saline (doses up to 20 mg have been used). Inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      may also be administered by metered dose inhaler (MDI) as 4 to 8 puffs with a spacer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin and glucose &ndash; With intravenous access, infusion of insulin and glucose can be given to mobilize extracellular potassium into the cells. Insulin administration drives extracellular potassium into the cells by enhancing the activity of the Na-K ATPase pump in skeletal muscles. Glucose is given concomitantly to prevent hypoglycemia. The effect of insulin begins in 10 to 20 minutes and peaks at 30 to 60 minutes. The major adverse effect is hypoglycemia, and serum glucose level should be measured one hour after the administration of insulin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and prevention of hyperkalemia in adults\", section on 'Insulin with glucose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to hypoglycemia in infants and children\", section on 'Clinical management'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"       regular insulin",
"      </a>",
"      (dose of 0.1 units per kg, maximum dose of 10 units) is given along with dextrose (glucose) dose of 0.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      over 30 minutes. The administration of dextrose is based upon the age of the patient as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children younger than five years of age: Give 10 percent dextrose (100",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      at a dose of 5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Children five years of age and older: Give 25 percent dextrose (250",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      at a dose of 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      (maximum dose 25 g)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      &ndash; Increasing the extracellular pH with sodium bicarbonate leads to hydrogen ion movement from the cell into the extracellular space. As a result, extracellular potassium moves into the cell to maintain electroneutrality. However, it remains uncertain whether or not sodium bicarbonate therapy is beneficial, and it should",
"      <strong>",
"       not",
"      </strong>",
"      be the only therapy used in the management of hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prevention of hyperkalemia in adults\", section on 'Sodium bicarbonate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children, the dose of bicarbonate is 1",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      (maximum dose 50 mEq) administered over 10 to 15 minutes. It can be given as 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of an 8.4 percent solution or, for children less than six months of age, as 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of a 4.2 percent solution. Although dosing can be repeated, there is a risk of developing hypernatremia with repetitive administration.",
"     </li>",
"     <li>",
"      In one case series of 21 children, a combination solution of a fixed concentration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      , insulin, glucose, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/883?source=see_link\">",
"       sodium acetate",
"      </a>",
"      (which is converted to bicarbonate) was shown to be safe and effective in treating hyperkalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/6\">",
"       6",
"      </a>",
"      ]. The advantage of this combination solution is that it can be infused continuously until a stable, lower potassium value has been obtained. The standardized concentrations of ingredients and the simple infusion regimen also can limit dosing errors. In this cohort, all but one child received the infusion through a central access, and concerns regarding extravasation injury when infused peripherally may limit its more widespread use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722119972\">",
"    <span class=\"h1\">",
"     TREATMENT OF REVERSIBLE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of etiologies can cause hyperkalemia. Many of these conditions are reversible, and management should focus on treating the underlying disease after ensuring initial management of patients with potentially life-threatening hyperkalemia, as discussed above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H266365934#H266365934\">",
"     \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include the following reversible causes of hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemia, which impairs renal excretion of potassium",
"     </li>",
"     <li>",
"      Congenital adrenal hyperplasia or adrenal insufficiency, which is corrected with hormonal therapy",
"     </li>",
"     <li>",
"      Discontinuation of mediations (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       spironolactone",
"      </a>",
"      ), which impair",
"      <strong>",
"       renal excretion of potassium",
"      </strong>",
"     </li>",
"     <li>",
"      Discontinuation of parental fluids or medications with excessively large loads of potassium",
"     </li>",
"     <li>",
"      Correction of metabolic acidosis, which promotes potassium transcellular movement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270662\">",
"    <span class=\"h1\">",
"     THERAPIES REMOVING POTASSIUM FROM THE BODY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three available modalities for potassium removal are diuretics, cation exchange resin, and dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270670\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop and thiazide diuretics can improve urinary potassium excretion in children with adequate effective volume and renal function. This intervention may be useful in children with persistently elevated but nonurgent levels of hyperkalemia (5.5 to 6.5",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    and as an adjunct in those with more severe hyperkalemia.",
"   </p>",
"   <p>",
"    In general, we use a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    , a loop diuretic, at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously. The normal maximum dose in children with normal renal function is 40 mg; however, in children with renal insufficiency, higher doses (up to 80 mg) may be required. If effective, furosemide may be given every six hours.",
"   </p>",
"   <p>",
"    However, diuretic therapy may have limited or no benefits in children with decreased effective circulating volume or moderate to severe renal dysfunction. In these patients, the use of cation exchange resins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialysis may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270677\">",
"    <span class=\"h2\">",
"     Enteral cation exchange resins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polystyrene sulfonates are cation exchange resins, which exchange sodium for potassium across the large intestine.",
"   </p>",
"   <p>",
"    In children,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    , the most commonly used cation exchanger, is administered at a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    every four hours (maximum dose 30 g). It is dissolved in water and is given enterally (oral or through a nasogastric tube) or as a retention enema. Each gram of resin may bind as much as 1 mEq of potassium, while releasing a comparable amount of sodium into the patient as the counter-ion. The onset of exchange is approximately one to two hours. The ensuing indigestible potassium polystyrene sulfonate complex is then excreted in the feces, thereby removing potassium from the body.",
"   </p>",
"   <p>",
"    In the past,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    had been mixed with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    to prevent intestinal obstruction caused by fecal impaction and constipation due to the concretion of the potassium polystyrene sulfonate complex. However, colonic necrosis and perforation have been reported in patients receiving this mixture, especially in the setting of post-gastrointestinal surgery or decreased colonic motility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/7\">",
"     7",
"    </a>",
"    ]. In 2009, the US Food and Drug Administration recommended that sodium polystyrene sulfonate should not be administered with sorbitol. As an alternative, patients can be given a laxative (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/41/26260?source=see_link\">",
"     polyethylene glycol 3350",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63381 \" href=\"UTD.htm?5/56/6029\">",
"     table 3",
"    </a>",
"    )) to reduce the constipating effects of polystyrene sulfonates.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    is not available, clinicians must consider whether treatment with sodium polystyrene sulfonate in sorbitol is necessary.",
"   </p>",
"   <p>",
"    Cation exchangers are not beneficial in the emergent setting as they have limited or no short-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4279/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, it is a reasonable to initiate cation exchange resin therapy as soon as possible, especially in cases with (or suspected) persistent hyperkalemia, as it is the only therapy short of dialysis that can remove potassium from the body in most hyperkalemic children. Cation exchange therapy is used in patients with persistently moderately elevated potassium (5.5 to 6.5",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    and as an adjunct for those with more severe hyperkalemia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=see_link\">",
"     Sodium polystyrene sulfonate",
"    </a>",
"    should not be given to the following patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of hyperkalemia in adults\", section on 'Intestinal necrosis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postoperative patients",
"     </li>",
"     <li>",
"      Patients with an ileus or who are receiving opiates",
"     </li>",
"     <li>",
"      Patients with a large or small bowel obstruction",
"     </li>",
"     <li>",
"      Preterm infants",
"     </li>",
"     <li>",
"      The use of",
"      <strong>",
"       oral",
"      </strong>",
"      sodium polystyrene should be avoided in all term neonates. Rectal administration should also",
"      <strong>",
"       not",
"      </strong>",
"      be administered to term infants who are at risk for intestinal hypomobility",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      necrotizing enterocolitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635270684\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children unresponsive to diuretic or cation exchange resin therapy, or with severe renal dysfunction, dialysis may be necessary to remove excess potassium from the body. Generally, hemodialysis is the preferred modality to reduce potassium levels as it is the quickest and most controlled renal replacement treatment. Although peritoneal dialysis can be used, potassium removal is less efficient and less well controlled. In some centers, other forms of continuous renal replacement may be a better option than hemodialysis because of increased availability due to local resources and staffing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=see_link&amp;anchor=H4746438#H4746438\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Modality choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722120029\">",
"    <span class=\"h1\">",
"     CHRONIC HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pediatric hyperkalemia is most commonly seen in children with chronic kidney disease. In these patients, medical therapy consists of a low potassium diet, use of loop diuretic therapy, correction of metabolic acidosis with carbonate therapy, and possible intermittent use of sodium polystyrene sulfate. If medical therapy fails to control hyperkalemia, renal replacement therapy must be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635271454\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia in children is caused by derangements of the hemostatic mechanisms that normally regulate potassium balance (",
"      <a class=\"graphic graphic_table graphicRef85965 \" href=\"UTD.htm?18/36/19020\">",
"       table 1",
"      </a>",
"      ). The most common causes of true hyperkalemia are due to impaired urinary potassium excretion, transcellular movement of potassium into the extracellular space, and less frequently excessive potassium intake. However, the most common cause of an elevated potassium level is pseudohyperkalemia, which is typically caused by a hemolyzed blood sample. (See",
"      <a class=\"local\" href=\"#H691997633\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urgency and type of intervention are based on the degree of potassium elevation, presence or absence of symptoms, and electrocardiographic findings. The most serious manifestations of hyperkalemia are cardiac conduction abnormalities and arrhythmias, which generally occur when potassium concentration is &ge;7.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      with chronic hyperkalemia or possibly at lower levels with an acute rise in serum potassium. (See",
"      <a class=\"local\" href=\"#H691997633\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958377#H85958377\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Cardiac conduction abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because hyperkalemia is a potentially life-threatening condition, initial acute management of elevated potassium takes precedence over any diagnostic evaluation. (See",
"      <a class=\"local\" href=\"#H691997633\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management steps include (",
"      <a class=\"graphic graphic_table graphicRef85978 \" href=\"UTD.htm?27/41/28318\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Confirmation that the patient is truly hyperkalemic, especially if the clinical setting makes the diagnosis of hyperkalemia unlikely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958478#H85958478\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H266365994#H266365994\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Pseudohyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While awaiting confirmation of hyperkalemia, obtain an electrocardiogram (ECG) and place the patient on a cardiac monitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=see_link&amp;anchor=H85958377#H85958377\">",
"       \"Causes, diagnosis, and evaluation of hyperkalemia in children\", section on 'Cardiac conduction abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe hyperkalemia (potassium level greater than 7.0",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      those with lower potassium values and ECG changes other than peaked T waves, we recommend administrating rapid transient therapeutic interventions directed towards counteracting the adverse cardiac effects (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Slow infusion of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      10 percent solution at a dose of 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      (maximum dose 20 mL [2 g]). (See",
"      <a class=\"local\" href=\"#H635270648\">",
"       'Cardiac membrane stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy to shift extracellular potassium into cells including: (1) intravenous administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"       regular insulin",
"      </a>",
"      and glucose,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      (2) inhaled beta-adrenergic agonists, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol (salbutamol)",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H635270655\">",
"       'Therapies shifting potassium into intracellular space'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      also causes transcellular potassium movement, but its beneficial effect is uncertain. As a result, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend the use of sodium bicarbonate as the sole intervention to shift potassium intracellularly (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H635270655\">",
"       'Therapies shifting potassium into intracellular space'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After initial management of the child with potentially life-threatening hyperkalemia or those who present with more modest hyperkalemia, further management consists of identification and treatment of reversible causes. These include correction of hypovolemia (impaired renal urinary excretion)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metabolic acidosis (transcellular movement), and hormonal therapy for hypoaldosteronism caused by congenital adrenal hyperplasia and primary adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H722119972\">",
"       'Treatment of reversible causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy to remove bodily potassium includes diuretics, cation exchange resin, and dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diuretics and cation exchange resin are used in patients with persistent, moderately elevated potassium (5.5 to 6.5",
"      <span class=\"nowrap\">",
"       mEq/L),",
"      </span>",
"      and as an adjunct for those with more severe hyperkalemia. (See",
"      <a class=\"local\" href=\"#H635270670\">",
"       'Diuretics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H635270677\">",
"       'Enteral cation exchange resins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis therapy is reserved for patients with persistent hyperkalemia who are unresponsive to diuretic or cation exchange therapy. In general, hemodialysis is the preferred modality to reduce potassium levels, as it is the quickest and most controlled renal replacement treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent pediatric hyperkalemia is most commonly seen in children with chronic kidney disease. In these patients, medical therapy consists of a low potassium diet, use of loop diuretic therapy, correction of metabolic acidosis with carbonate therapy, and intermittent use of sodium polystyrene sulfate. If medical therapy fails to control hyperkalemia, renal replacement therapy must be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Hyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/1\">",
"      Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005; :CD003235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/2\">",
"      Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. Arch Dis Child 2012; 97:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/3\">",
"      Winkler AW, Hoff HE, Smith PK. Factors affecting the toxicity of potassium. Am J Physiol 1939; 127:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/4\">",
"      Helfrich E, de Vries TW, van Roon EN. Salbutamol for hyperkalaemia in children. Acta Paediatr 2001; 90:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/5\">",
"      Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates. J Pediatr 2002; 141:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/6\">",
"      Janjua HS, Mahan JD, Patel HP, et al. Continuous infusion of a standard combination solution in the management of hyperkalemia. Nephrol Dial Transplant 2011; 26:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4279/abstract/7\">",
"      Bomback AS, Woosley JT, Kshirsagar AV. Colonic necrosis due to sodium polystyrene sulfate (Kayexalate). Am J Emerg Med 2009; 27:753.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85908 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4279=[""].join("\n");
var outline_f4_11_4279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H635271454\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H635271753\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691997633\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H635270633\">",
"      RAPID THERAPY TO COUNTERACT CARDIAC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691998055\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691998062\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H635270648\">",
"      - Cardiac membrane stabilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H635270655\">",
"      - Therapies shifting potassium into intracellular space",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722119972\">",
"      TREATMENT OF REVERSIBLE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H635270662\">",
"      THERAPIES REMOVING POTASSIUM FROM THE BODY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H635270670\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H635270677\">",
"      Enteral cation exchange resins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H635270684\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722120029\">",
"      CHRONIC HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H635271454\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/85908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/36/19020\" title=\"table 1\">",
"      Causes of pediatric hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/41/28318\" title=\"table 2\">",
"      Pediatric hyperkalemia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/56/6029\" title=\"table 3\">",
"      Laxatives for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25848?source=related_link\">",
"      Causes, diagnosis, and evaluation of hyperkalemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=related_link\">",
"      Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4280="Sexuality in palliative care";
var content_f4_11_4280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sexuality in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Timothy J Moynihan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Sharon L Bober, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Susan D Block, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4280/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness. The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family caregivers; and coordination across sites of care. Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sexuality is an important issue for some patients nearing the end of their life as well as their sexual partners, and yet this is a subject that health care professionals often do not address [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Sexuality is intrinsic to a person's sense of self throughout the lifespan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and it can be a vital form of expression that helps to relieve suffering, offer meaning, and maintain interpersonal connection in the face of life-limiting illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/6\">",
"     6",
"    </a>",
"    ]. Sexuality does not refer to just a physical act but more broadly encompasses identity, gender roles and orientations, eroticism, pleasure, and intimacy. It is experienced and may be expressed through thoughts and feelings in addition to behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues related to sexuality in palliative care. A more in depth discussion as to the general approach to patients with sexual dysfunction is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data on sexuality for patients who are undergoing palliative care, there appears to be a high prevalence of sexual dysfunction in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. In addition, the frequency and type of sexual dysfunction among patients in palliative care appears to vary by the underlying disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/10,12-17\">",
"     10,12-17",
"    </a>",
"    ]. Representative findings on the scope of this issue are given below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 65 patients admitted to an acute pain and palliative care unit, 86 percent considered sexuality important enough that they wanted to talk about it with a knowledgeable clinician [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of over 400 patients with heart failure, 59 percent reported sexual dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 65 patients with advanced cancer (25 male, 40 female), 52 percent reported no sexual intercourse and only 11 percent reported mild to good frequency of intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/10\">",
"       10",
"      </a>",
"      ]. Sexual satisfaction was reported as good, mild, insufficient, and nonexistent in 12, 12, 30 and 46 percent, respectively. Sexual satisfaction was significantly associated with age, performance status, and self reported well being. &nbsp;",
"     </li>",
"     <li>",
"      Concerns about decreased libido are reported by at least 21 percent of patients enrolled in palliative care programs, although these figures are higher in specific populations. For example, 56 to 80 percent of patients with amyotrophic lateral sclerosis (ALS) or progressive multiple sclerosis report problems with libido [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/12-15\">",
"       12-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with advanced cancer, 57 percent of females and 68 percent of males rated sexual quality of life as an important factor [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the high incidence of sexual dysfunction and the clear importance of these issues to patients, the limited data suggest that only a minority of patients enrolled in palliative care programs report ever being asked about concerns related to sexuality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/19\">",
"     19",
"    </a>",
"    ]. This may be attributed to some discomfort in approaching sexuality by health care workers. In one study involving 348 patients at 16 difference hospice settings, hospice staff reported a lack of sufficient information to assess issues with sexual interest or activity in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105380576\">",
"    <span class=\"h2\">",
"     Partner's perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexuality is also important to the partner of patients with advanced disease. In one study, 84 percent of those whose partner had a cancer of the reproductive system and 76 percent of those whose partner had another type of cancer reported a negative impact on their sexual relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/21\">",
"     21",
"    </a>",
"    ]. These changes in sexuality and intimacy were associated with reports of self-blame, rejection, sadness, anger, and lack of sexual fulfillment among partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERCEIVED BARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because clinicians involved in the palliative care of patients often focus most of their time, attention, and effort on treatment on the primary disease process, associated symptoms, and its complications, little thought may go into evaluations regarding sexual health. However, many other barriers hindering the discussion about sexuality for patients in palliative care are similar to those in other areas of medicine including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of adequate training &mdash; Most health care professionals are not adequately trained in taking a sexual history [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. Clinicians who receive training in communication and sexuality are more likely to take a sexual history [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/23,25\">",
"       23,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assuming sexuality is only about intercourse &mdash; Health care providers may take a narrow view of sexuality by assuming it only encompasses one&rsquo;s capacity for sexual intercourse. Since patients in palliative care may be unable to engage in intercourse, clinicians may wrongly assume that sexuality is of little importance.",
"     </li>",
"     <li>",
"      Assuming older patients and those without a partner are not interested in sexuality &mdash; Providers may not recognize the importance of sexuality in the palliative care setting, particularly as it relates to older patients and those who lack a partner. Despite this, data from other areas of medicine consistently show that this is not the case [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. As an example, in one study of healthy older adults in the US, 73, 53, and 26 percent of respondents who were aged 57 to 64, 65 to 74, and 75 to 85, respectively were sexually active [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assuming treatments are not available &mdash; Providers may feel that little can be done to help terminally ill patients who have sexual dysfunction and that treatment would not be effective. Despite this, interventions that facilitate flexible coping (ie, interventions aimed at helping patients and partners broaden the way they conceptualize sexuality and intimacy) can improve sexual and relationship satisfaction across the continuum of care, including at the end of life [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of sexual dysfunction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Provider discomfort &mdash; Providers may feel embarrassed or unprepared to discuss sexual issues [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/29\">",
"       29",
"      </a>",
"      ]. This may be due to differences between the individual patient and the provider in relation to culture, socioeconomic status, age, gender, and race. In addition, providers may be uncomfortable taking sexual histories from patients whose sexual orientation is different from their own [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/24\">",
"       24",
"      </a>",
"      ]. This can result in a stigmatization of sexual minority patients who may perceive themselves as being &ldquo;invisible&rdquo; to their providers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While it is unrealistic to expect that all clinicians involved in the palliative care of patients become experts in sexual care and counseling, they should be able to screen for sexual dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distress. If identified as a significant issue for patients and their partners, appropriate referral may be made to other specialists or health care providers when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link&amp;anchor=H14#H14\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\", section on 'Barriers to history taking'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TAKING A SEXUAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exploration of the patient's (and partner's) concerns and beliefs about sexual function may uncover issues that can be addressed through specific therapeutic maneuvers, educational materials, or simple reassurance. A non-judgmental, accepting, empathetic attitude and the use of open-ended questions in an environment that is conducive to the sensitive nature of the discussion can foster communication. In general, when taking a sexual history, the terminology used by the clinician should be understood by the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link&amp;anchor=H13#H13\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\", section on 'Sexual history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of some routine questions that can be asked during the patient interview include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;What are some of the things that you and your partner do to feel close in daily life? How is this working for you?&rdquo;",
"     </li>",
"     <li>",
"      \"Many of my patients with similar conditions have questions about sexual function and how their disease impacts sexuality. Do you have anything you would like to ask?\"",
"     </li>",
"     <li>",
"      &ldquo;Has this illness changed the way that you feel about yourself?&rdquo;",
"     </li>",
"     <li>",
"      \"The kind of treatment you have received can make it difficult to be intimate with your partner. Is this something you would like to talk about?\"",
"     </li>",
"     <li>",
"      \"Is a physical relationship with your partner an important part of your life, and has your current illness significantly impacted this?\"",
"     </li>",
"     <li>",
"      \"Finding private time alone may be difficult in your current living situation. Is this a problem for you and your partner?\"",
"     </li>",
"     <li>",
"      &ldquo;Is there anything we can do to help you regain the experience of intimacy with your partner?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATING SEXUAL DYSFUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101648054\">",
"    <span class=\"h2\">",
"     Addressing sexual health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ex-PLISSIT model for addressing sexuality and sexual health is appropriate for palliative care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/30\">",
"     30",
"    </a>",
"    ]. It emphasizes the need for reflection and review as well as the importance of consistent follow-up. This mnemonic model, which extends the original PLISSIT model [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/31\">",
"     31",
"    </a>",
"    ], can be helpful in deciding which problems may be addressed by the primary clinician and who should be referred for specialized care. Permission-giving is both the first step of addressing sexuality with patients and also a key aspect of subsequent stages in the model.",
"   </p>",
"   <p>",
"    The Ex-PLISSIT model has four stages of treatment; the first three can be performed by any clinician.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Permission giving (P) &mdash; The first stage can be accomplished by indicating (giving \"permission\") to patients that sexuality is still normal, and that sexual problems are a valid concern even near the end of life. Permission-giving also invites patients to initiate a dialogue about their concerns and allows for discussion on potential interventions tailored to their needs.",
"      <br/>",
"      <br/>",
"      Once the clinician learns the patient is suffering from sexual dysfunction, an assessment exploring possible contributory factors should follow. A general discussion of organic versus psychological causes of sexual dysfunction is provided elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link&amp;anchor=H15#H15\">",
"       \"The sexual history and approach to the patient with sexual dysfunction\", section on 'Assessment and intervention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited information (LI) &mdash; This involves acknowledging that sexual health concerns are both valid and common. The aim is to normalize sexual health concerns for patients. As an example, anxiety over the safety of sexual activity may be present in both the patient and his or her partner (who may fear causing discomfort or harm to the patient through sexual intercourse). Indicating that such concerns are not uncommon and can result in anxiety in many people in a similar situation can be reassuring to patients and allow them to more openly discuss their own situation.",
"     </li>",
"     <li>",
"      Specific suggestions (SS) &mdash; Specific suggestions need to address all aspects of sexual health, including concerns about role changes and self-esteem. Specific suggestions include rendering specific advice on issues raised, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The use of a lubricant for a woman who complains of excessive vaginal dryness",
"     </li>",
"     <li>",
"      Removing a television from the bedroom to encourage proper sleep hygiene",
"     </li>",
"     <li>",
"      Experimenting with different sexual positions to reduce discomfort",
"     </li>",
"     <li>",
"      Installing a lock on the bedroom door to address privacy concerns",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, simple and specific suggestions for intimacy that may be appropriate include focusing on touch, massage, cuddling, and intimate communication in place of sexual intercourse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive therapy (IT) &mdash; For clinicians who find themselves without the prerequisite skill set to further discuss sexual health issues with patients, a referral to a specialist for intensive therapy is appropriate. Reasons may also include more in-depth counselling for prior traumatic events (eg, a prior rape or sexual abuse) or for further discussion about sexual therapeutics. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Issues specific to end of life care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful history taking with attention to medications (both prescription and over the counter), alcohol use, prior treatments, current symptoms, and comorbid conditions is essential. While this is not necessarily different from evaluation of sexual dysfunction in patients who are not nearing the end of life, there are some unique issues that are specific to these patients in palliative care:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should ask about the presence of specific symptoms such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fatigue &mdash; Fatigue is one of the most commonly reported symptoms in patients receiving palliative care, and it can clearly impact sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Many clinicians are unaware that fatigue can be treated, even in patients who are nearing the end of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6922?source=see_link&amp;anchor=H29611100#H29611100\">",
"       \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"       \"Cancer-related fatigue: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyspnea &mdash; Dyspnea is a common complaint in patients in palliative care programs, affecting up to 50 percent of patients in some series [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/33\">",
"       33",
"      </a>",
"      ]. It can have a major impact on quality of life, including sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/34\">",
"       34",
"      </a>",
"      ]. Sometimes a maneuver as simple as changing sexual positions or sexual roles (ie, aggressive versus passive) may be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30666?source=see_link\">",
"       \"Assessment and management of dyspnea in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Depression &mdash; Depression is common in patients enrolled in palliative care programs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. One of the cardinal symptoms is loss of interest or pleasure in activities like sexual intercourse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"       \"Assessment and management of depression in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of medications is essential &mdash; Multiple medications known to inhibit sexual function are commonly administered in palliative care, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antidepressants &mdash; Many of the newest and most effective antidepressants of the serotonin reuptake inhibitor class (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) are burdened by sexual side effects, which can diminish both libido and erectile function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Opioids &mdash; Opioids can interfere with sexual function, regardless of the delivery route employed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Many palliative care patients receive chronic opioid therapy which is known to lower testosterone levels in men and lead to amenorrhea in women [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H13#H13\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Effects on the hypothalamic-pituitary-adrenal axis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continued active therapies &mdash; Although many patients in palliative care are no longer receiving anticancer treatment, this may not be the case universally. Therefore, it is important to recognize that the effects of treatments, particularly anticancer treatment, include sexual dysfunction, which may be more prominent in women than men [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"       \"Ovarian failure due to anticancer drugs and radiation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alterations in body image can be quite dramatic at the end of life &mdash; Changes in physical appearance can be related to the underlying disease state or from treatments themselves. Unfortunately, such changes may play a larger role in sexual dysfunction in palliative care patients than in other settings. The presence of percutaneous drainage or feeding tubes, tracheostomies, colostomies, chronic draining wounds, or decubitus ulcers with accompanying foul odors can impede sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/42\">",
"       42",
"      </a>",
"      ]. Once these issues are recognized, health care professionals can attempt to create innovative solutions. Trained stoma therapy nurses or technicians can be of great assistance in such cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of patients with a colostomy or ileostomy\", section on 'Lifestyle issues'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45302109\">",
"    <span class=\"h1\">",
"     ADDRESSING THE PARTNER'S NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be sensitive to issues in the spouse or partner and help to direct them to local resources that may be helpful. The issues surrounding a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness affect more than just the patient; they affect those closest to him or her. Therefore, changes in sexuality due to advanced disease often have a profound impact on partners as well as on the couple&rsquo;s relationship itself [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As partners shift into roles of primary caregiver, established sexual roles and normative expectations may be significantly altered due to caregiver duties, burdens, and potentially burnout. Partners may find themselves unsure of how to express affection, how to alternate between their multiple new roles and how to communicate about their own needs for intimacy as their loved one approaches the end of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients (and their partners) should be reassured that if they have enjoyed a close sexual relationship, it can continue to be part of their relationship, even at the end of life. For many patients and their partners, sexual activity takes on a different form and meaning as they face the end of life. With rare exceptions, procreation is no longer the goal of sexual activity. Patients tend to report greater emphasis on emotional connection and expressions of intimacy and closeness rather than on physical expressions of sexuality. Massage, touch, sharing, reflection, cuddling, and other intimate activities may serve as an alternate way to express affection and love [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/19,44\">",
"     19,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Understanding the concerns and needs of the patient and partner for sexuality can greatly enhance the health care team's ability to offer help and solutions. In general, as it is in patients who are not at the end of life, treatment should be directed at the underlying cause, if one is identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Specific interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122184841\">",
"    <span class=\"h3\">",
"     Hormonal manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most treatments for sexual dysfunction are appropriate for palliative care patients, including the use of hormone replacement therapy to help restore vaginal health in women and libido in men. However, certain treatments may not be appropriate for some patients.",
"   </p>",
"   <p>",
"    For example, while multiple studies in postmenopausal women have shown improved libido and sexual function with testosterone therapy along with estrogen replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/45-50\">",
"     45-50",
"    </a>",
"    ], use of testosterone in the absence of estrogen was not effective in improving libido in female cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, women with hormone receptor-positive breast cancer may not be comfortable taking hormonally based therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H22#H22\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Personal history of breast cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020386#H150020386\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Effect of testosterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101648061\">",
"    <span class=\"h3\">",
"     Discontinuing medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful review of medications may identify ones that are contributing to sexual dysfunction and can be discontinued. This includes medications not directed towards the palliation of symptoms such as those originally initiated to prevent worsening of a chronic medical condition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the risk of complications in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101648068\">",
"    <span class=\"h3\">",
"     Addressing range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased flexibility and mobility can be major impediments to sexual activity. If appropriate to the goals of care, physical therapy and an evaluation for rehabilitation (with specific attention to sexuality) may be of great help.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101648075\">",
"    <span class=\"h3\">",
"     Importance of privacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of privacy is a major impediment to sexual activity for patients confined to nursing homes, hospitals, or hospice inpatient units. Most inpatient care facilities are not equipped to allow sexual contact. Rooms may not be private, and even those that are often have no locks on doors or other mechanisms to preclude unwanted intrusions by staff, visitors, or other residents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients also know that their lives are freely discussed among the staff and this may be enough to inhibit sexual behaviors. In addition, hospital beds, which tend to be single, do not easily accommodate two people. These beds often make physical intimacy such as sustained holding and caressing more difficult.",
"   </p>",
"   <p>",
"    Allowing patients privacy in institutional settings where little privacy otherwise exists can be helpful. In one hospice, a telephone system is available where intimacy can be shared via telephone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4280/abstract/52\">",
"     52",
"    </a>",
"    ]. While this does not allow for tactile interactions, patients and partners have viewed the program favorably. Care facilities should develop systems where patients can have quality, protected private times with their partners without fear of interruption. Providing items necessary for sexual intimacy and safety, such as lubricants and condoms, is relatively simple and can help provide for whole patient care that is the touchstone of palliative care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101648088\">",
"    <span class=\"h3\">",
"     Multidisciplinary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidisciplinary team approach may be needed to adequately address sexual dysfunction in palliative care patients. Depending on the case, team members may include clinicians, nurses, enterostomal and physical therapists, social workers, psychiatrists, psychologists, pharmacists, spiritual advisors, or others who may be unique to the individual patient circumstances. It is often useful for palliative care settings to identify a working list of key resources, including providers such as sexual health counselors that can be made available to patients and partners. Understanding the specific concerns and needs of the patient and his or her partner for sexual expression will greatly enhance the health care team's ability to offer help and solutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexuality is an important issue for patients with an advanced, serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life-threatening illness who are nearing the end of their life as well as their partners. The frequency of sexual dysfunction is highly dependent upon the specific disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Scope of the problem'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the high incidence of sexual dysfunction and the importance of these issues to patients and their partners, most patients enrolled in palliative care programs are not asked about concerns related to sexuality. Many of the barriers to improving sexuality in end of life care are similar to those that hinder efforts to deal with sexual issues in all areas of medicine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Perceived barriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exploration of the patient's (and partner's) concerns and beliefs about sexual function may uncover issues that can be addressed by specific therapeutic maneuvers, educationally, or through simple reassurance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Taking a sexual history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with sexual dysfunction, a thorough assessment exploring all possible contributory factors should be carried out. Patients should be specifically asked about fatigue, dyspnea, depression, and altered body image. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluating sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ex-PLISSIT model of sex therapy is useful for counseling and is appropriate for palliative care patients. (See",
"      <a class=\"local\" href=\"#H101648054\">",
"       'Addressing sexual health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, as it is in patients who are not at the end of life, treatment should be directed at the underlying cause, if one is identified. Most treatments for sexual dysfunction are appropriate for palliative care patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/1\">",
"      Howlett, C, Swain, M, Fitzmaurice, N, et al. Sexuality: The neglected component in palliative care. Int J Palliat Nurs 1997; 3:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/2\">",
"      Katz A. The sounds of silence: sexuality information for cancer patients. J Clin Oncol 2005; 23:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/3\">",
"      Redelman MJ. Is there a place for sexuality in the holistic care of patients in the palliative care phase of life? Am J Hosp Palliat Care 2008; 25:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/4\">",
"      Ginsberg TB, Pomerantz SC, Kramer-Feeley V. Sexuality in older adults: behaviours and preferences. Age Ageing 2005; 34:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/5\">",
"      Bretschneider JG, McCoy NL. Sexual interest and behavior in healthy 80- to 102-year-olds. Arch Sex Behav 1988; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/6\">",
"      Hordern AJ, Currow DC. A patient-centred approach to sexuality in the face of life-limiting illness. Med J Aust 2003; 179:S8.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Sexual Health. Available at http:/www.who.int/reproductive-health/gender/sexual_health.htlm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/8\">",
"      Ende J, Rockwell S, Glasgow M. The sexual history in general medicine practice. Arch Intern Med 1984; 144:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/9\">",
"      Pauly I, Goldstein S. Prevalence of significant sexual problems in medical practice. Med Aspects Hum Sex 1979; 48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/10\">",
"      Vitrano V, Catania V, Mercadante S. Sexuality in patients with advanced cancer: a prospective study in a population admitted to an acute pain relief and palliative care unit. Am J Hosp Palliat Care 2011; 28:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/11\">",
"      Hoekstra T, Lesman-Leegte I, Luttik ML, et al. Sexual problems in elderly male and female patients with heart failure. Heart 2012; 98:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/12\">",
"      Anderson H, Ward C, Eardley A, et al. The concerns of patients under palliative care and a heart failure clinic are not being met. Palliat Med 2001; 15:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/13\">",
"      Demirkiran M, Sarica Y, Uguz S, et al. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler 2006; 12:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/14\">",
"      Wasner M, Bold U, Vollmer TC, Borasio GD. Sexuality in patients with amyotrophic lateral sclerosis and their partners. J Neurol 2004; 251:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/15\">",
"      Stolp-Smith KA, Carter JL, Rohe DE, Knowland DP 3rd. Management of impairment, disability, and handicap due to multiple sclerosis. Mayo Clin Proc 1997; 72:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/16\">",
"      Ketta E, Cayan F, Akbay E, et al. Sexual dysfunction and associated risk factors in women with end-stage renal disease. J Sex Med 2008; 5:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/17\">",
"      Santos PR, Capote JR Jr, Cavalcanti JU, et al. Quality of life among women with sexual dysfunction undergoing hemodialysis: a cross-sectional observational study. Health Qual Life Outcomes 2012; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/18\">",
"      Rouanne M, Massard C, Hollebecque A, et al. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer 2013; 49:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/19\">",
"      Lemieux L, Kaiser S, Pereira J, Meadows LM. Sexuality in palliative care: patient perspectives. Palliat Med 2004; 18:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/20\">",
"      Kutner JS, Kassner CT, Nowels DE. Symptom burden at the end of life: hospice providers' perceptions. J Pain Symptom Manage 2001; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/21\">",
"      Hawkins Y, Ussher J, Gilbert E, et al. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: the experience of partners in a sexual relationship with a person with cancer. Cancer Nurs 2009; 32:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/22\">",
"      Gamel C, Davis BD, Hengeveld M. Nurses' provision of teaching and counselling on sexuality: a review of the literature. J Adv Nurs 1993; 18:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/23\">",
"      Ross PE, Landis SE. Development and evaluation of a sexual history-taking curriculum for first- and second-year family practice residents. Fam Med 1994; 26:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/24\">",
"      Merrill JM, Laux LF, Thornby JI. Why doctors have difficulty with sex histories. South Med J 1990; 83:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/25\">",
"      Tsimtsiou Z, Hatzimouratidis K, Nakopoulou E, et al. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med 2006; 3:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/26\">",
"      Zilbergeld B. Group treatment of sexual dysfunction in men without partners. J Sex Marital Ther 1975; 1:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/27\">",
"      Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/28\">",
"      Reese JB, Keefe FJ, Somers TJ, Abernethy AP. Coping with sexual concerns after cancer: the use of flexible coping. Support Care Cancer 2010; 18:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/29\">",
"      Park ER, Bober SL, Campbell EG, et al. General internist communication about sexual function with cancer survivors. J Gen Intern Med 2009; 24 Suppl 2:S407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/30\">",
"      Taylor B, Davis S. Using the extended PLISSIT model to address sexual healthcare needs. Nurs Stand 2006; 21:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/31\">",
"      Annon J. The PLISSIT model. J Sex Educ Ther 1967; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/32\">",
"      Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/33\">",
"      Modonesi C, Scarpi E, Maltoni M, et al. Impact of palliative care unit admission on symptom control evaluated by the edmonton symptom assessment system. J Pain Symptom Manage 2005; 30:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/34\">",
"      Sturesson M. Life satisfaction in subjects with chronic obstructive pulmonary disease. Work 2000; 14:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/35\">",
"      Lloyd-Williams M. Is it appropriate to screen palliative care patients for depression? Am J Hosp Palliat Care 2002; 19:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/36\">",
"      Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994; 151:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/37\">",
"      Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage 1994; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/38\">",
"      Paice JA, Penn RD. Amenorrhea associated with intraspinal morphine. J Pain Symptom Manage 1995; 10:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/39\">",
"      Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004; 100:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/40\">",
"      Mirin SM, Meyer RE, Mendelson JH, Ellingboe J. Opiate use and sexual function. Am J Psychiatry 1980; 137:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/41\">",
"      Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/42\">",
"      Roberge C, Tran M, Massoud C, et al. Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. Br J Cancer 2000; 82:263.",
"     </a>",
"    </li>",
"    <li>",
"     Manne S, Badr H. Social relationships and cancer. In: Support Processes in Intimate Relationships, Davila J, Sullivan K.  (Eds), Oxford Press, 2010. p.240.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/44\">",
"      Cort, E, Monroe, B, Oliviere, D. Couples in palliative care. Sex Marital Ther 2004; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/45\">",
"      Nathorst-B&ouml;&ouml;s J, Fl&ouml;ter A, Jarkander-Rolff M, et al. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido--effects on sexuality and psychological general well-being. Maturitas 2006; 53:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/46\">",
"      Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/47\">",
"      Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/48\">",
"      Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/49\">",
"      Goldstat R, Briganti E, Tran J, et al. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/50\">",
"      Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst 2007; 99:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/51\">",
"      Bauer M. Their only privacy is between their sheets. Privacy and the sexuality of elderly nursing home residents. J Gerontol Nurs 1999; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4280/abstract/52\">",
"      Skinner D. Intimacy and the telephone. Caring 2001; 20:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2204 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4280=[""].join("\n");
var outline_f4_11_4280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105380576\">",
"      Partner's perspective",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERCEIVED BARRIERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TAKING A SEXUAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATING SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101648054\">",
"      Addressing sexual health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Issues specific to end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45302109\">",
"      ADDRESSING THE PARTNER'S NEEDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Specific interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H122184841\">",
"      - Hormonal manipulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101648061\">",
"      - Discontinuing medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101648068\">",
"      - Addressing range of motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101648075\">",
"      - Importance of privacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101648088\">",
"      - Multidisciplinary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6922?source=related_link\">",
"      Palliative care: Overview of fatigue, weakness, and asthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4281="Therapeutic endoscopic ultrasound";
var content_f4_11_4281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic endoscopic ultrasound",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Kenneth E Fasanella, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Michael K Sanders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4281/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H131645430\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) was developed as a diagnostic modality but rapidly gained a role for a variety of therapeutic applications. EUS has been used increasingly for drainage of pancreatic pseudocysts, treatment of cystic lesions of the pancreas, EUS-guided cholangiopancreatography, localized therapy for pancreatic tumors, and treatment of subepithelial lesions and gastric varices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645438\">",
"    <span class=\"h1\">",
"     DRAINAGE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS is well-suited to safely drain fluid collections of various types in areas accessible from the stomach, duodenum, or rectum. The most abundant experience has been with drainage of pancreatic pseudocysts, but case reports have described a variety of drainage procedures, including a hepatic abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/1\">",
"     1",
"    </a>",
"    ], subphrenic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/2\">",
"     2",
"    </a>",
"    ], pelvic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], bilomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], and infected gallbladders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645446\">",
"    <span class=\"h2\">",
"     Pseudocysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional endoscopic approach to transmural drainage of pseudocysts relies on the presence of an intraluminal bulge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accurate cross-sectional imaging techniques to detect the location of the pseudocyst and determine the distance between the pseudocyst and gastric wall. Despite this information, avoidance of interposed vasculature can be challenging.",
"   </p>",
"   <p>",
"    The technique of EUS-guided drainage starts with localization of the pseudocyst with EUS. A 19-gauge needle is then directed into the pseudocyst, with care being taken to avoid interposed vasculature. A guidewire is then introduced into the cavity under fluoroscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56108 \" href=\"UTD.htm?13/3/13360\">",
"     image 1",
"    </a>",
"    ), followed by transmural balloon dilation of the tract into the pseudocyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71061 \" href=\"UTD.htm?17/22/17760\">",
"     image 2",
"    </a>",
"    ). It is often difficult to place a dilating balloon catheter across the stomach wall. When this occurs, creating a fistulous tract with a push dilating catheter, a needle-knife, or a cystenterostome may aid with balloon placement. Once the tract is dilated, one or more plastic stents are placed into the pseudocyst cavity (",
"    <a class=\"graphic graphic_picture graphicRef68706 \" href=\"UTD.htm?31/5/31839\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72482 \" href=\"UTD.htm?35/37/36433\">",
"     picture 2",
"    </a>",
"    ) for drainage.",
"   </p>",
"   <p>",
"    EUS-guided drainage from the duodenum can be technically challenging because the oblique view from a linear echoendoscope makes endoscopic visualization more difficult than a standard side-viewing duodenoscope. Ongoing development of forward-viewing and side-viewing echoendoscopes may improve these technical limitations and improve endoscopic visualization.",
"   </p>",
"   <p>",
"    The endoscopic management of pancreatic pseudocysts is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"     \"Endoscopic management of pseudocysts of the pancreas: Efficacy and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=see_link\">",
"     \"Endoscopic management of pseudocysts of the pancreas: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645454\">",
"    <span class=\"h2\">",
"     Subphrenic abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have described drainage of subphrenic abscesses in two patients under EUS guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/2\">",
"     2",
"    </a>",
"    ]. In an illustrative report, the abscess was perisplenic, measuring 4 x 5.5 cm, in a patient with portal hypertension and multiple venous collaterals in the region, which were thought to be too high risk for a percutaneous approach. The second case was a 5 x 2.5 cm left subphrenic abscess complicating a Nissen fundoplication. In both cases, the cysts were punctured using a linear array echoendoscope, followed by placement of a 0.035 inch guidewire, looping it inside the cyst. Over the wire, a 7 Fr naso-abscess drainage catheter was placed along with an adjacent 10 Fr double pigtail catheter. The catheters were flushed with 500 cc sterile saline three times per day and removed after eight days. The patients were both treated with imipenem for the first five days. The stents were removed after repeat EUS at four weeks later demonstrated complete resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645462\">",
"    <span class=\"h2\">",
"     Hepatic abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report described a patient with a 7 x 11 cm left lobe hepatic abscess that was drained using a similar technique as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/2\">",
"     2",
"    </a>",
"    ] under EUS guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/1\">",
"     1",
"    </a>",
"    ]. The abscess was flushed three times daily through a nasobiliary catheter for seven days. A stent was not placed. The patient did well without recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645470\">",
"    <span class=\"h2\">",
"     Bilomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described successful drainage of a biloma with EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The largest report described four patients with bile leaks and gallbladder fossa bilomas who were drained via EUS-guided double pigtail stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/6\">",
"     6",
"    </a>",
"    ]. ERCP was performed initially with placement of a biliary endoprosthesis. Subsequently, a 19-gauge needle was used to access the biloma from the stomach or proximal duodenum, a 0.035 inch guidewire was used to secure access, and 6 to 8 mm balloon dilators were used to dilate the fistula. In one case, a single pigtail stent was placed, and in the other three, one to two double pigtail stents were left in place to drain the bilomas. The size of the fluid collections ranged from 4 x 2 cm up to 8 x 6 cm. Antibiotic coverage was given the day of the procedure and for 10 to 14 days afterward. The duration of drainage was 11 days in one case, and one to three months in the others. No complications were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645478\">",
"    <span class=\"h2\">",
"     Gallbladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy is generally preferred for management of acute cholecystitis but is not always an option due to comorbidities. For patients with severe sepsis who do not respond to medical therapy, transcutaneous cholecystostomy or transpapillary drainage of the cystic duct has been performed as a temporary measure to clear the infection until surgery is feasible.",
"   </p>",
"   <p>",
"    Case series have also demonstrated the feasibility of EUS-guided gallbladder drainage in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series included nine patients with acute cholecystitis who were deemed poor surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/9\">",
"     9",
"    </a>",
"    ]. The gallbladder was punctured from the duodenal bulb or the stomach and dilation was performed with 7 Fr bougie dilation catheters, followed by placement of a 5 Fr nasocholecystic tube. Seven of the nine patients subsequently underwent surgical cholecystectomy (six laparoscopic, one open) without complication, and the other two had the drainage tube removed without complication once the cholecystitis had clinically resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645486\">",
"    <span class=\"h2\">",
"     Pelvic abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have described drainage of pelvic and perirectal abscesses by EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One series involved 25 patients with abscesses that were predominantly postsurgical or posttraumatic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with abscesses less than 8 cm in size were treated with two 7 Fr transrectal stents. If the abscess was 8 cm or more in size, a 10 Fr drainage catheter was also placed. The drainage catheter was removed once the abscess had decreased in size by at least 50 percent, and the stents were removed after two weeks. The abscesses were successfully drained in all of the patients at the time of EUS and there were no procedure-related complications. In 24 patients, there was complete resolution of the abscesses on follow-up CT at two weeks.",
"   </p>",
"   <p>",
"    Another case series included 12 patients with abscesses mostly from pelvic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/4\">",
"     4",
"    </a>",
"    ]. Stents were inserted successfully in nine patients, resulting in complete resolution of the abscesses in eight, and incomplete resolution in one with a large cyst (&gt;8 cm) that required subsequent surgical management. Stents were removed after three to six months. In the three patients who were not amenable to stent placement, two had recurrence of the abscess following aspiration. No major complications were encountered. The only significant difference in technique to the drainage procedures described above was the use of a needle-knife for puncture of the abscess wall prior to guidewire insertion and balloon dilation.",
"   </p>",
"   <p>",
"    These data suggest EUS-guidance can be a safe, effective technique for drainage of pelvic abscesses. Placement of drainage catheters or stents appears to be crucial for successful resolution, since recurrence rates are high with aspiration alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645494\">",
"    <span class=\"h1\">",
"     FINE-NEEDLE INJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS permits precise targeting for the delivery of various substances directly into pancreas, liver, or subepithelial lesions. EUS-guided injection of ethanol for celiac plexus neurolysis has been performed for over a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. More recently, EUS-guided fine-needle injection (FNI) of various substances has been reported for treatment of gastrointestinal stromal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/14\">",
"     14",
"    </a>",
"    ], insulinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/15\">",
"     15",
"    </a>",
"    ], hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/16\">",
"     16",
"    </a>",
"    ], esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], cystic neoplasms of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and pancreatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645502\">",
"    <span class=\"h2\">",
"     Cystic neoplasms of the pancreas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ablative therapies administered by EUS for the treatment of pancreatic cystic neoplasms is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H24#H24\">",
"     \"Pancreatic cystic neoplasms\", section on 'Experimental methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645510\">",
"    <span class=\"h2\">",
"     Gastrointestinal stromal tumors (GISTs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of concentrated ethanol for ablation of subepithelial lesions of the stomach was reported more than 30 years ago in 54 patients who were poor surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/23\">",
"     23",
"    </a>",
"    ]. More recently, EUS-FNI (1.5 mL of 95 percent ethanol directly into the tumor in a single session) was used to treat a 4 cm symptomatic GIST in the stomach of a poor surgical candidate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/14\">",
"     14",
"    </a>",
"    ]. Treatment was associated with complete resolution of the tumor. The patient developed abdominal pain one week after the injection, and ulcer formation documented on endoscopy seven weeks after the injection, which had healed by the follow-up EUS at six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645518\">",
"    <span class=\"h2\">",
"     Insulinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described EUS-FNI of a symptomatic 13 mm insulinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/15\">",
"     15",
"    </a>",
"    ]. The tumor was ablated after injecting 8 cc of 95 percent ethanol in four 2 mL aliquots. No tumor recurrence was observed based upon surveillance EUS or development of recurrent symptoms after 34 months of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645526\">",
"    <span class=\"h2\">",
"     Hepatic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described percutaneous ablation of hepatic metastases with ethanol injection. Ablation with EUS-FNI has been described only in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/16\">",
"     16",
"    </a>",
"    ]. The patient had a solitary liver metastasis from rectal cancer, measuring 1.6 cm that was not amenable to percutaneous approach due to vascular interposition. Ethanol, at a concentration of 95 percent and a volume averaging 6 mL, was used during multiple EUS-FNI sessions several weeks apart.",
"   </p>",
"   <p>",
"    The patient had a good response, with disappearance of the lesion and a decrease in CEA level. He eventually had an additional lesion that was treated similarly with four sessions with a good response. The only complication was a subcapsular hematoma after one procedure. At the time of the report, the patient was still alive and in relatively good health 5.5 years after the initial diagnosis of metastatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645534\">",
"    <span class=\"h2\">",
"     Pancreatic adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various biologic anti-tumor agents have been introduced into pancreatic cancers under EUS-guided FNI for control of locally advanced disease. Although long-term results are not well studied, preliminary results suggest these approaches are generally safe and may prove to be an adjunct or alternative to traditional chemoradiation therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645542\">",
"    <span class=\"h3\">",
"     Cytoimplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-guided intratumoral injection for the treatment of advanced pancreatic cancer was first reported in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/21\">",
"     21",
"    </a>",
"    ]. The study evaluated the safety and feasibility of injecting a mixed lymphocyte culture of donor and host mononuclear cells (cytoimplant) into the tumor with EUS-guided FNI. It was hypothesized that the mixed lymphocyte reaction would result in activation of immune effector cells and release of cytokines with tumor suppressive properties.",
"   </p>",
"   <p>",
"    Of eight patients, two had partial responses and one a minor response with a median survival of 13.2 months. There were no procedure-related complications. Although no additional studies of cytoimplant have been reported, this was the first study to demonstrate the safety and feasibility of EUS-guided FNI for the treatment of locally advanced tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196737562\">",
"    <span class=\"h3\">",
"     TNFerade(TM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNFerade",
"    <sup>",
"     TM",
"    </sup>",
"    is a replication-deficient adenoviral vector that contains the human TNF-alpha gene regulated by Egr-1, a chemoradiation inducible promoter. When combined with subsequent chemoradiation, TNF-alpha levels in the tumor increase, potentially leading to tumor suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter study (presented as an abstract) described transfer of TNFerade",
"    <sup>",
"     TM",
"    </sup>",
"    into locally advanced pancreatic cancer via endoscopic ultrasound or percutaneous (PTA) guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/25\">",
"     25",
"    </a>",
"    ]. Of the 37 patients treated, stabilization of tumor was observed in 83 percent at one month and 74 percent at three months. Tumor area reduction of greater than 25 percent at one month and 50 percent at three months occurred in 31 and 11 percent of cases, respectively. Survival without overall progression was 63 percent at one month and 47 percent at three months. The therapy was generally well tolerated and considered safe and effective.",
"   </p>",
"   <p>",
"    A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study found less promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/26\">",
"     26",
"    </a>",
"    ]. TNFerade was injected into locally advanced pancreatic carcinomas in 50 patients. Only 20 patients (40 percent) were free from local progression at three months.",
"   </p>",
"   <p>",
"    In March 2010, a phase III trial using TNFerade&trade; injections into locally advanced pancreatic adenocarcinoma was terminated early when interim analysis showed only an 8 percent lower risk of death with projected inability to reach a statistically significant improvement in outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645558\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial brachytherapy is used for treatment of various cancers including head, neck, breast, lung, prostate, and gastrointestinal tract. After radioactive seed placement, the target tissue is exposed to gamma radiation, producing localized tissue injury and tumor ablation. A potential advantage of brachytherapy over traditional external beam radiotherapy is limited radiation toxicity to surrounding normal tissue. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The radioactive seeds are usually implanted under CT-guidance or during laparotomy. However, EUS-guided brachytherapy has been reported for head and neck tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/27\">",
"     27",
"    </a>",
"    ], recurrent esophageal cancer with perigastric adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/17\">",
"     17",
"    </a>",
"    ], and pancreatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative series included 15 patients with unresectable pancreatic cancer who underwent EUS-guided implantation of an average of 22 radioactive seeds [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/22\">",
"     22",
"    </a>",
"    ]. During a median follow-up of 11 months, 27 percent of patients demonstrated a \"partial\" tumor response, 20 percent showed a \"minimal\" response, and 33 percent demonstrated \"stable disease.\" Clinical benefit was shown in up to 30 percent of patients, mostly due to a reduction in pain.",
"   </p>",
"   <p>",
"    Pancreatitis occurred in three patients with formation of a pseudocyst in two of the three patients. However, these adverse events were considered mild and treated conservatively without additional therapy. This study demonstrated that EUS-guided brachytherapy was technically feasible and generally well tolerated, but more studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645566\">",
"    <span class=\"h2\">",
"     Oncogel",
"    </span>",
"    &nbsp;&mdash;&nbsp;OncoGel (MacroMed Inc, West Valley, Utah) is a chemotherapeutic formulation for intralesional injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    for local treatment of unresectable solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/29\">",
"     29",
"    </a>",
"    ]. This product uses a thermosensitive, biodegradable copolymer, ReGel, to deliver paclitaxel to solid tumors, providing continuous controlled-release into the surrounding tissue for up to six weeks. OncoGel is undergoing clinical studies within the United States for the treatment of incurable lung and breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645574\">",
"    <span class=\"h2\">",
"     Esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, TNFerade(TM), an adenoviral vector that carries the transgene encoding human TNF-alpha, has been used for treatment of locally advanced esophageal cancer and pancreatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H196737562\">",
"     'TNFerade(TM)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A multicenter Phase I clinical trial (published in abstract form) reported experience with 24 patients who had stage II and III esophageal cancer, using escalating doses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/18\">",
"     18",
"    </a>",
"    ]. The vector was injected directly into the tumors, 18 patients with traditional endoscopy and six with EUS-FNI. Results were promising with minimal morbidity, and a 40 percent pathologic complete response in the top three dose cohorts. At the time of the final report, median follow up was 42.9 months, and three- and five-year disease free survival rates were 57 and 52 percent, respectively. Further studies have not been published. There was a non-significant trend toward increased efficacy but prolonged procedure times using EUS compared with traditional endoscopy.",
"   </p>",
"   <p>",
"    A case report described the use of EUS-FNI to place specially adapted brachytherapy beads for nodal spread of esophageal squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/17\">",
"     17",
"    </a>",
"    ]. A 66 year old woman with T3 N1 M0 disease had disease recurrence manifested by celiac lymph node recurrence after neoadjuvant chemotherapy and external beam radiation, and surgical resection with gastric pull-through. The celiac lymph node was treated with CT-guided brachytherapy bead placement. Subsequent recurrence manifested by two lymph nodes at the diaphragmatic crus was not amenable to percutaneous placement; as a result, EUS-FNI was used. Two I(125) beads were placed that had been designed to fit within a 19-gauge needle, which was sealed with sterile bone wax to prevent a bead from prematurely dislodging from the needle. No recurrence was detected at eight months follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645582\">",
"    <span class=\"h2\">",
"     GI bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of EUS in the setting of gastrointestinal bleeding has been evaluated in a few small series for specific situations, including refractory bleeding lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/31\">",
"     31",
"    </a>",
"    ] and esophageal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/32\">",
"     32",
"    </a>",
"    ] and gastric varices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645590\">",
"    <span class=\"h3\">",
"     Refractory bleeding lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS guidance was used for treatment by FNI into lesions with at least two failures of hemostasis by conventional endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/31\">",
"     31",
"    </a>",
"    ]. The series included one Dieulafoy's lesion and one pancreatic pseudoaneurysm successfully treated with 99 percent ethanol, and one duodenal ulcer and two GISTs treated with cyanoacrylate. No rebleeding was observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645598\">",
"    <span class=\"h3\">",
"     Esophageal varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controlled trial included 48 patients who were randomly assigned to sclerotherapy of esophageal varices using EUS guidance or using standard endoscopy with ethanolamine as the sclerosant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no significant difference in the number of sessions required for obliteration (4.1 versus 4.3) or time to successful obliteration (59 versus 63 days). No difference was observed in variceal recurrence rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645606\">",
"    <span class=\"h3\">",
"     Gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two series evaluated EUS-guided injection for treatment of actively bleeding gastric varices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series used 0.5 mL cyanoacrylate (CYA) and 0.7 mL lipiodol, comparing \"on demand\" injection after the index procedure (reserved for recurrent bleeding) in 47 patients with scheduled biweekly procedures in 54 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/34\">",
"       34",
"      </a>",
"      ]. Successful obliteration of varices was observed in 80 percent of patients in an average of just over two sessions, spanning approximately five weeks. A median of three doses of cyanoacrylate was required for obliteration. Repeated procedures on a scheduled basis significantly reduced the frequency of late rebleeding.",
"     </li>",
"     <li>",
"      A prospective series of five patients with bleeding gastric varices described experience with EUS-guided injection of 1 mL of 1:1 CYA-lipiodol or Glubran2-lipiodol, focusing on localization of the perforating veins as the target for injection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/33\">",
"       33",
"      </a>",
"      ]. Hemostasis was achieved in all five patients. Eradication of the varices was successful in two patients after one session, and in three patients after two sessions (mean 1.6). There were no cases of recurrent bleeding over a 10-month follow-up period, and no complications were encountered. The authors noted that EUS-FNI may have an advantage over traditional endoscopy due to a lack of need for good endoscopic visualization to target the injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645614\">",
"    <span class=\"h2\">",
"     Botulinum toxin for achalasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two case series reported the use of EUS-FNI of botulinum toxin directly into the lower esophageal sphincter to ensure proper localization of the injection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The first included four patients with achalasia who were deemed poor operative candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/35\">",
"     35",
"    </a>",
"    ]. All four had durable responses after 5 to 13 months follow-up.",
"   </p>",
"   <p>",
"    The second included three patients, with reportedly good results and objective improvement on manometry and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, but with follow-up limited to one month [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645622\">",
"    <span class=\"h2\">",
"     Botulinum toxin for the treatment of obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-guided botulinum toxin injection into antrum has been studied for the treatment of obesity in a pilot study. In the study, 10 patients received an EUS-guided injection of 100 or 300 units of botulinum toxin into the muscularis propria of the antrum and were then followed for 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/37\">",
"     37",
"    </a>",
"    ]. The maximum tolerated volume during a nutrient drink test (a measure of satiety) decreased significantly from 1380 mL at baseline to 620 mL two weeks after injection, though the decrease was only statistically significant in those who received 300 units of botulinum toxin. Gastric emptying was not significantly prolonged in patients who received the higher dose. The mean weight loss was 5 kg after 16 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645630\">",
"    <span class=\"h1\">",
"     EUS-GUIDED TISSUE ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common clinical dilemma is the management of cystic and neuroendocrine tumors. Given the variability in clinical behavior and morbidity of surgical resection, local therapy would be an attractive option if adequate safety and efficacy data were available. While prospective human trials documenting safety and efficacy of treating pancreatic cystic lesions already exist [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], solid tissue ablation in the pancreas has been described only in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/15\">",
"     15",
"    </a>",
"    ]. As a result, use of these techniques outside of desperate situations and research protocols awaits human trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645638\">",
"    <span class=\"h1\">",
"     EUS-GUIDED CELIAC PLEXUS BLOCK (CPB) AND CELIAC PLEXUS NEUROLYSIS (CPN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of EUS-guided celiac plexus block and neurolysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645646\">",
"    <span class=\"h1\">",
"     EUS-GUIDED CHOLANGIOPANCREATOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-guided cholangiopancreatography has evolved as a technique",
"    <strong>",
"    </strong>",
"    for gaining access to the bile ducts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pancreatic duct in patients where conventional ERCP has failed or was not possible due to altered surgical anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. Due to the close proximity to the gastrointestinal tract, the left intrahepatic ducts, common bile duct, and main pancreatic duct are well visualized with EUS and can be accessed with either a transgastric or transduodenal approach.",
"   </p>",
"   <p>",
"    As a general rule, three EUS-guided approaches have been used to decompress the biliary system:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creation of a choledochoduodenal fistula with stent placement",
"     </li>",
"     <li>",
"      Creation of a cholangiogastric fistula with stent placement",
"     </li>",
"     <li>",
"      EUS-guided rendezvous through accessing either the left intrahepatic ducts or common bile duct with conversion to conventional endoscopic retrograde cholangiopancreatography (ERCP) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68598 \" href=\"UTD.htm?24/47/25334\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an illustrative report, 23 patients underwent EUS-guided cholangiography for biliary drainage after failed ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/43\">",
"     43",
"    </a>",
"    ]. Thirteen underwent intrahepatic intervention with EUS-guided access from the stomach into the left intrahepatic ducts using either a 19- or 22-gauge needle. In 11 patients, a transpapillary stent was placed with one patient requiring the creation of a cholangiogastric fistula and placement of a double pigtail stent for biliary decompression. The obstruction resolved in 12 of 13 patients for a success rate of 92 percent. The one patient in whom intervention was unsuccessful had primary sclerosing cholangitis with multiple strictures precluding passage of a guidewire.",
"   </p>",
"   <p>",
"    Extrahepatic intervention was attempted in 10 patients with successful placement of a biliary stent in nine. Two patients underwent creation of a choledochoduodenal fistula and one required a choledochogastric fistula. The single failure occurred in a patient with an impacted stone that required percutaneous transhepatic drainage with subsequent stent internalization. Complications included bile leak, minor bleeding, and self-limited pneumoperitoneum. Overall, the success rate was 91 percent with a complication rate of 17 percent and only one major complication (bile leak, 4 percent).",
"   </p>",
"   <p>",
"    The same group also published their experience with EUS-guided drainage of the main pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/44\">",
"     44",
"    </a>",
"    ]. Thirteen patients with failed ERCP underwent EUS-guided pancreaticogastrostomy for endoprosthesis placement and decompression of the main pancreatic duct. Successful drainage was established in 10 of 13 patients (77 percent). Complications included one case of bleeding treated with endoclip placement and one case of a contained perforation. No major complications were encountered.",
"   </p>",
"   <p>",
"    EUS-guided cholangiopancreatography is technically feasible and relatively safe in the hands of experienced interventional endoscopists skilled in both ERCP and EUS. This technique offers a potential alternative to surgery in patients in whom conventional ERCP is unsuccessful or not possible. However, the risk of complications including biliary peritonitis, pancreatitis, bleeding, perforation, and stent migration needs to be evaluated in larger numbers of patients with longer follow-up to determine the true potential for this approach. Currently, this procedure should be reserved for tertiary centers with highly skilled endoscopists using a multidisciplinary approach (ie, pancreatic surgeons, interventional radiologists) to these challenging cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645654\">",
"    <span class=\"h1\">",
"     EUS-GUIDED FIDUCIAL PLACEMENT FOR CYBERKNIFE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CyberKnife stereotactic radiotherapy (Accuray, Sunnyvale, CA) delivers multiple beams of precisely directed radiation to a tumor using real-time image guidance. Radiographic markers (fiducials) are implanted at the tumor site as reference points to assist in targeting the radiation beams.",
"   </p>",
"   <p>",
"    Fiducials have traditionally been placed surgically or percutaneously under ultrasound or computed tomography guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. More recently, case series have demonstrated the feasibility of placing them with EUS. In one series, for example, EUS was used to place fiducials in patients with tumors located in the mediastinum, retrocardiac region, retrocrural region, esophagogastric junction, porta hepatis, and pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/48\">",
"     48",
"    </a>",
"    ]. Placement was successful in 11 of 13 patients (85 percent) with one failure secondary to gastric outlet obstruction precluding endosonographic visualization of the tumor, and the second failure due to intervening vasculature with increased risk for bleeding with needle puncture. Of 13 patients, seven were treated for pancreatic cancer with successful fiducial placement in 100 percent.",
"   </p>",
"   <p>",
"    The technique for fiducial placement was similar to the previously mentioned approach for EUS-guided brachytherapy. After loading the fiducial into a 19-gauge needle and partially withdrawing the stylet to allow room, the fiducial is placed under EUS guidance near the treatment field (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59445 \" href=\"UTD.htm?28/37/29265\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81971 \" href=\"UTD.htm?36/24/37250\">",
"     image 5",
"    </a>",
"    ) to assist monitoring of respiratory variation under fluoroscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50550 \" href=\"UTD.htm?26/30/27104\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A single complication occurred after fiducial placement in a patient with porta hepatis lymph node metastasis from colorectal cancer. The patient was admitted 25 days after the procedure for cholangitis and treated with antibiotics and percutaneous biliary drainage. Following this case, all patients were treated with prophylactic antibiotics followed by a three-day course after the procedure.",
"   </p>",
"   <p>",
"    Another series (reported in abstract form) described experience with EUS-guided fiducial placement in patients with unresectable gastrointestinal malignancies (ie, pancreatic cancer, cholangiocarcinoma, recurrent gastric and colon cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/49\">",
"     49",
"    </a>",
"    ]. Fiducials were successfully placed in 15 of 16 (94 percent) patients with no adverse clinical outcomes.",
"   </p>",
"   <p>",
"    In our own published experience, 51 patients underwent EUS-guided fiducial placement for locally advanced (n = 36) or recurrent (n = 15) pancreatic cancer. Successful placement was achieved in 90 percent, with spontaneous migration in 7 percent and technical failure in 8 percent (all in patients with recurrent cancer after pancreaticoduodenectomy). Only one complication of mild pancreatitis occurred in a patient who underwent simultaneous celiac plexus neurolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS-guided fiducial placement for stereotactic radiosurgery appears to be safe and feasible. However, additional studies are needed to determine the efficacy of this approach with CyberKnife radiotherapy. Infectious complications may be reduced by using sterile precautions and prophylactic antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196737579\">",
"    <span class=\"h1\">",
"     EUS-GUIDED FINE-NEEDLE TATTOO FOR PREOPERATIVE LOCALIZATION OF SMALL PANCREATIC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small pancreatic tumors may be difficult to locate during minimally invasive surgeries such as laparoscopic enucleation and laparoscopic distal pancreatectomy (LDP). EUS-guided fine-needle tattoo (EUS-FNT) was first described for the preoperative localization of a pancreatic insulinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/51\">",
"     51",
"    </a>",
"    ]. Since then, several case reports and case series have demonstrated the efficacy and safety of this technique for both pancreatic endocrine tumors (PET) and pancreatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Once the tumor is localized with EUS, fine-needle injection is performed with various dyes (eg, india ink, purified carbon particles [SPOT],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    ) to tattoo the tumor (",
"    <a class=\"graphic graphic_picture graphicRef70994 \" href=\"UTD.htm?40/46/41703\">",
"     picture 3",
"    </a>",
"    ). EUS-FNT may provide better localization of small tumors, thereby limiting the amount of resected pancreatic parenchyma, an important goal for a minimally invasive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645662\">",
"    <span class=\"h1\">",
"     EUS-GUIDED ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-guided angiography is a potential alternative to the traditional percutaneous route for accessing the vascular system. Studies in animals have demonstrated feasibility in accessing the portal vein, thoracic and abdominal aorta, celiac axis, superior mesenteric artery, splenic artery, splenic vein, and hepatic vein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The risks, benefits, and complications need to be carefully investigated before its role in humans becomes clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645670\">",
"    <span class=\"h1\">",
"     FORWARD-VIEWING CURVILINEAR ARRAY ECHOENDOSCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, oblique-viewing curvilinear array echoendoscopes have been used for therapeutic EUS procedures. However, these instruments are limited by impaired endoscopic visualization, difficult orientation for EUS-guided drainage procedures, and difficulty passing accessory instruments through the endoscope channel. A prototype forward-viewing therapeutic curvilinear array echoendoscope (GIF-UCT 160J-AL5; Olympus America Inc., Center Valley, PA) was developed in an effort to overcome some of these limitations. Initial reports have demonstrated success with this instrument in both diagnostic and therapeutic EUS procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4281/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Additional studies are needed to determine whether this prototype instrument offers advantages over current technology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131645678\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy and safety of therapeutic endoscopic ultrasound (EUS) is evolving. It has been used for drainage of pancreatic pseudocysts, treatment of cystic and neuroendocrine neoplasms of the pancreas, EUS-guided cholangiopancreatography, localized therapy for pancreatic tumors, and treatment of subepithelial lesions and gastric varices.",
"     </li>",
"     <li>",
"      At present, therapeutic EUS should be limited to tertiary centers with experienced endoscopists, interventional radiologists, and surgeons.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/1\">",
"      Seewald S, Imazu H, Omar S, et al. EUS-guided drainage of hepatic abscess. Gastrointest Endosc 2005; 61:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/2\">",
"      Seewald S, Brand B, Omar S, et al. EUS-guided drainage of subphrenic abscess. Gastrointest Endosc 2004; 59:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/3\">",
"      Varadarajulu S, Drelichman ER. EUS-guided drainage of pelvic abscess (with video). Gastrointest Endosc 2007; 66:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/4\">",
"      Giovannini M, Bories E, Moutardier V, et al. Drainage of deep pelvic abscesses using therapeutic echo endoscopy. Endoscopy 2003; 35:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/5\">",
"      Varadarajulu S, Drelichman ER. Effectiveness of EUS in drainage of pelvic abscesses in 25 consecutive patients (with video). Gastrointest Endosc 2009; 70:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/6\">",
"      Shami VM, Talreja JP, Mahajan A, et al. EUS-guided drainage of bilomas: a new alternative? Gastrointest Endosc 2008; 67:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/7\">",
"      Ponnudurai R, George A, Sachithanandan S, et al. Endoscopic ultrasound-guided drainage of a biloma: a novel approach. Endoscopy 2006; 38:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/8\">",
"      Kahaleh M, Wang P, Shami VM, et al. Drainage of gallbladder fossa fluid collections with endoprosthesis placement under endoscopic ultrasound guidance: a preliminary report of two cases. Endoscopy 2005; 37:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/9\">",
"      Lee SS, Park do H, Hwang CY, et al. EUS-guided transmural cholecystostomy as rescue management for acute cholecystitis in elderly or high-risk patients: a prospective feasibility study. Gastrointest Endosc 2007; 66:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/10\">",
"      Kwan V, Eisendrath P, Antaki F, et al. EUS-guided cholecystenterostomy: a new technique (with videos). Gastrointest Endosc 2007; 66:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/11\">",
"      Baron TH, Topazian MD. Endoscopic transduodenal drainage of the gallbladder: implications for endoluminal treatment of gallbladder disease. Gastrointest Endosc 2007; 65:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/12\">",
"      Wiersema MJ, Wiersema LM. Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc 1996; 44:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/13\">",
"      Wiersema M, Sandusky D, Carr R, et al. Endosonography Guided Celiac Plexus Neurolysis (Eus Cpn) in Patients with Pain Due to Intraabdominal (Ia) Malignancy. Gastrointest Endosc 1995; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/14\">",
"      G&uuml;nter E, Lingenfelser T, Eitelbach F, et al. EUS-guided ethanol injection for treatment of a GI stromal tumor. Gastrointest Endosc 2003; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/15\">",
"      J&uuml;rgensen C, Schuppan D, Neser F, et al. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006; 63:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/16\">",
"      Barclay RL, Perez-Miranda M, Giovannini M. EUS-guided treatment of a solid hepatic metastasis. Gastrointest Endosc 2002; 55:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/17\">",
"      Lah JJ, Kuo JV, Chang KJ, Nguyen PT. EUS-guided brachytherapy. Gastrointest Endosc 2005; 62:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/18\">",
"      Pinto H, Chang KJ, Reid TR, et al. Final report of a phase I evaluation of TNFerade biologic plus chemoradiotherapy prior to esophagectomy for locally advanced resectable esophageal cancer. J Clin Oncol 2011; 29:AB e13610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/19\">",
"      Gan SI, Thompson CC, Lauwers GY, et al. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc 2005; 61:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/20\">",
"      Oh HC, Seo DW, Lee TY, et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc 2008; 67:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/21\">",
"      Chang KJ, Nguyen PT, Thompson JA, et al. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer 2000; 88:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/22\">",
"      Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy 2006; 38:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/23\">",
"      Otani T, Tatsuka T, Kanamaru K, Okuda S. Intramural injection of ethanol under direct vision for the treatment of protuberant lesions of the stomach. Gastroenterology 1975; 69:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/24\">",
"      Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/25\">",
"      Chang KJ, Senzer N, Chung T, et al. A novel gene transfer therapy against pancreatic cancer (TNFerade) delivered by endoscopic ultrasound (EUS) and percutaneous guided fine needle injection (FNI). Gastrointest Endosc 2004; 59:Ab92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/26\">",
"      Hecht JR, Farrell JJ, Senzer N, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 2012; 75:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/27\">",
"      Maier W, Henne K, Krebs A, Schipper J. Endoscopic ultrasound-guided brachytherapy of head and neck tumours. A new procedure for controlled application. J Laryngol Otol 1999; 113:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/28\">",
"      Jin Z, Du Y, Li Z, et al. Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study. Endoscopy 2008; 40:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/29\">",
"      Zentner GM, Rathi R, Shih C, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/30\">",
"      Vukelja SJ, Anthony SP, Arseneau JC, et al. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007; 18:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/31\">",
"      Levy MJ, Wong Kee Song LM, Farnell MB, et al. Endoscopic ultrasound (EUS)-guided angiotherapy of refractory gastrointestinal bleeding. Am J Gastroenterol 2008; 103:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/32\">",
"      de Paulo GA, Ardengh JC, Nakao FS, Ferrari AP. Treatment of esophageal varices: a randomized controlled trial comparing endoscopic sclerotherapy and EUS-guided sclerotherapy of esophageal collateral veins. Gastrointest Endosc 2006; 63:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/33\">",
"      Romero-Castro R, Pellicer-Bautista FJ, Jimenez-Saenz M, et al. EUS-guided injection of cyanoacrylate in perforating feeding veins in gastric varices: results in 5 cases. Gastrointest Endosc 2007; 66:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/34\">",
"      Lee YT, Chan FK, Ng EK, et al. EUS-guided injection of cyanoacrylate for bleeding gastric varices. Gastrointest Endosc 2000; 52:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/35\">",
"      Hoffman BJ, Knapple WL, Bhutani MS, et al. Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Gastrointest Endosc 1997; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/36\">",
"      Maiorana A, Fiorentino E, Genova EG, et al. Echo-guided injection of botulinum toxin in patients with achalasia: initial experience. Endoscopy 1999; 31:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/37\">",
"      Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg 2008; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/38\">",
"      Wiersema MJ, Sandusky D, Carr R, et al. Endosonography-guided cholangiopancreatography. Gastrointest Endosc 1996; 43:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/39\">",
"      Giovannini M, Moutardier V, Pesenti C, et al. Endoscopic ultrasound-guided bilioduodenal anastomosis: a new technique for biliary drainage. Endoscopy 2001; 33:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/40\">",
"      Burmester E, Niehaus J, Leineweber T, Huetteroth T. EUS-cholangio-drainage of the bile duct: report of 4 cases. Gastrointest Endosc 2003; 57:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/41\">",
"      Bories E, Pesenti C, Caillol F, et al. Transgastric endoscopic ultrasonography-guided biliary drainage: results of a pilot study. Endoscopy 2007; 39:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/42\">",
"      Mallery S, Matlock J, Freeman ML. EUS-guided rendezvous drainage of obstructed biliary and pancreatic ducts: Report of 6 cases. Gastrointest Endosc 2004; 59:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/43\">",
"      Kahaleh M, Hernandez AJ, Tokar J, et al. Interventional EUS-guided cholangiography: evaluation of a technique in evolution. Gastrointest Endosc 2006; 64:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/44\">",
"      Kahaleh M, Hernandez AJ, Tokar J, et al. EUS-guided pancreaticogastrostomy: analysis of its efficacy to drain inaccessible pancreatic ducts. Gastrointest Endosc 2007; 65:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/45\">",
"      King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/46\">",
"      Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. Neurosurg Focus 2003; 15:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/47\">",
"      Whyte RI, Crownover R, Murphy MJ, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 2003; 75:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/48\">",
"      Pishvaian AC, Collins B, Gagnon G, et al. EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. Gastrointest Endosc 2006; 64:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/49\">",
"      Ellsmere JC, Mahadevan A, Kelleher T, et al. EUS-Guided radiotherapy fiducials for upper gastrointestinal malignancies. Gastrointest Endosc 2007; 65:Ab208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/50\">",
"      Sanders MK, Moser AJ, Khalid A, et al. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc 2010; 71:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/51\">",
"      Gress FG, Barawi M, Kim D, Grendell JH. Preoperative localization of a neuroendocrine tumor of the pancreas with EUS-guided fine needle tattooing. Gastrointest Endosc 2002; 55:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/52\">",
"      Ashida R, Yamao K, Okubo K, et al. Indocyanine green is an ideal dye for endoscopic ultrasound-guided fine-needle tattooing of pancreatic tumors. Endoscopy 2006; 38:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/53\">",
"      Farrell JJ, Sherrod A, Parekh D. EUS-guided fine-needle tattooing for preoperative localization of early pancreatic adenocarcinoma. Gastrointest Endosc 2009; 69:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/54\">",
"      Lennon AM, Newman N, Makary MA, et al. EUS-guided tattooing before laparoscopic distal pancreatic resection (with video). Gastrointest Endosc 2010; 72:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/55\">",
"      Lai L, Poneros J, Santilli J, Brugge W. EUS-guided portal vein catheterization and pressure measurement in an animal model: a pilot study of feasibility. Gastrointest Endosc 2004; 59:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/56\">",
"      Giday SA, Clarke JO, Buscaglia JM, et al. EUS-guided portal vein catheterization: a promising novel approach for portal angiography and portal vein pressure measurements. Gastrointest Endosc 2008; 67:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/57\">",
"      Magno P, Ko CW, Buscaglia JM, et al. EUS-guided angiography: a novel approach to diagnostic and therapeutic interventions in the vascular system. Gastrointest Endosc 2007; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/58\">",
"      Voermans RP, Eisendrath P, Bruno MJ, et al. Initial evaluation of a novel prototype forward-viewing US endoscope in transmural drainage of pancreatic pseudocysts (with videos). Gastrointest Endosc 2007; 66:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/59\">",
"      Trevino JM, Varadarajulu S. Initial experience with the prototype forward-viewing echoendoscope for therapeutic interventions other than pancreatic pseudocyst drainage (with videos). Gastrointest Endosc 2009; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4281/abstract/60\">",
"      Larghi A, Lecca PG, Ardito F, et al. Evaluation of hilar biliary strictures by using a newly developed forward-viewing therapeutic echoendoscope: preliminary results of an ongoing experience. Gastrointest Endosc 2009; 69:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2653 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4281=[""].join("\n");
var outline_f4_11_4281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H131645678\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645430\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645438\">",
"      DRAINAGE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645446\">",
"      Pseudocysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645454\">",
"      Subphrenic abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645462\">",
"      Hepatic abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645470\">",
"      Bilomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645478\">",
"      Gallbladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645486\">",
"      Pelvic abscesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645494\">",
"      FINE-NEEDLE INJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645502\">",
"      Cystic neoplasms of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645510\">",
"      Gastrointestinal stromal tumors (GISTs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645518\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645526\">",
"      Hepatic metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645534\">",
"      Pancreatic adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H131645542\">",
"      - Cytoimplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196737562\">",
"      - TNFerade(TM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645558\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645566\">",
"      Oncogel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645574\">",
"      Esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645582\">",
"      GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H131645590\">",
"      - Refractory bleeding lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H131645598\">",
"      - Esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H131645606\">",
"      - Gastric varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645614\">",
"      Botulinum toxin for achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131645622\">",
"      Botulinum toxin for the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645630\">",
"      EUS-GUIDED TISSUE ABLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645638\">",
"      EUS-GUIDED CELIAC PLEXUS BLOCK (CPB) AND CELIAC PLEXUS NEUROLYSIS (CPN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645646\">",
"      EUS-GUIDED CHOLANGIOPANCREATOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645654\">",
"      EUS-GUIDED FIDUCIAL PLACEMENT FOR CYBERKNIFE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196737579\">",
"      EUS-GUIDED FINE-NEEDLE TATTOO FOR PREOPERATIVE LOCALIZATION OF SMALL PANCREATIC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645662\">",
"      EUS-GUIDED ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645670\">",
"      FORWARD-VIEWING CURVILINEAR ARRAY ECHOENDOSCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131645678\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2653|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/3/13360\" title=\"diagnostic image 1\">",
"      Fluorosc looping guidewire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/22/17760\" title=\"diagnostic image 2\">",
"      Transmural balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/47/25334\" title=\"diagnostic image 3\">",
"      EUS-guided cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/37/29265\" title=\"diagnostic image 4\">",
"      EUS fiducial placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/24/37250\" title=\"diagnostic image 5\">",
"      EUS fiducial pancreat tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/30/27104\" title=\"diagnostic image 6\">",
"      Fiducials pancreatic tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2653|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31839\" title=\"picture 1\">",
"      Fluorosc stent placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/37/36433\" title=\"picture 2\">",
"      Endosc double pigtail stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/46/41703\" title=\"picture 3\">",
"      Tattooed PET following preoperative EUS-FNT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4282="Conduction abnormalities after myocardial infarction";
var content_f4_11_4282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Conduction abnormalities after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/11/4282/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/11/4282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias and conduction disturbances are well-recognized complications of acute myocardial infarction (MI). They are induced by either autonomic imbalance or ischemia and necrosis of the conduction system. It is important to recognize which bradyarrhythmias are transient and which are likely to progress to irreversible and symptomatic high-degree block.",
"   </p>",
"   <p>",
"    The major conduction abnormalities associated with acute MI will be reviewed here; tachyarrhythmias, the other major dysrhythmic complication of MI, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link\">",
"     \"Supraventricular arrhythmias after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Issues related to LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two specific issues related to left bundle branch block (LBBB) in association with an acute MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LBBB can complicate the electrocardiographic diagnosis of MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"       \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a new or presumably new LBBB are treated as if they have an ST elevation MI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations of incidence and prognosis data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defining the incidence and prognostic significance of new conduction abnormalities associated with acute MI is complicated for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data are most commonly generated from retrospective reviews or sub-analyses of clinical trial data.",
"     </li>",
"     <li>",
"      Much of the data on bradyarrhythmias and bundle branch blocks (BBB) predate the development of primary reperfusion therapies (thrombolysis and primary PCI). By reducing infarct size, these therapies may also reduce the incidence of new conduction abnormalities, although the prognostic significance of new conduction abnormalities, when they occur, may be similar [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence or absence of bundle branch block (BBB) is usually determined on the initial ECG. It is frequently difficult to know how many of these abnormalities are chronic and how many are new abnormalities associated with the infarction. The HERO-2 trial suggested that new BBB developing after the initial ECG is rare in acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncertainty regarding the age of BBB also impacts the interpretation of prognostic data. Chronic and new conduction abnormalities may both predict poorer outcomes, but for different reasons: the former due to more extensive underlying cardiac disease and the latter due to the association with larger infarctions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY AND BLOOD SUPPLY OF THE CONDUCTION SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing the conduction disturbances that can occur after acute MI, it is helpful to first review some basic issues concerning the anatomy and blood supply of the conduction system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After leaving the AV node, the bundle of His divides at the juncture of the fibrous and muscular boundaries of the interventricular septum into the right and left bundle branches (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). The right bundle branch courses down the right side of interventricular septum near the endocardium in its upper third, deeper in the muscular portion of the septum in the middle third, and then again near the endocardium in its lower third. The right bundle does not branch throughout most of its course, but it begins to ramify as it approaches the base of the right anterior papillary muscle with fascicles going to the septal and free wall of the right ventricle.",
"   </p>",
"   <p>",
"    The main left bundle branch penetrates the membranous portion of the interventricular septum under the aortic ring. In short course, it divides into two or three fairly discrete branches [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A predivisional segment.",
"     </li>",
"     <li>",
"      An anterior fascicle that crosses the left ventricular outflow tract and terminates in the Purkinje system of the anterolateral wall of the left ventricle.",
"     </li>",
"     <li>",
"      A posterior fascicle that fans out extensively inferiorly and posteriorly.",
"     </li>",
"     <li>",
"      In about 65 percent of hearts, a separate fascicle to the interventricular septum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to fully understand the relationship between myocardial infarction and dysrhythmia, it is helpful to review the vascular supply of the different components of the conduction system (",
"    <a class=\"graphic graphic_figure graphicRef70956 \" href=\"UTD.htm?21/44/22213\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SA node &mdash; Supplied by the right coronary artery (RCA) in 60 percent of patients; by the left circumflex artery (LCX) in 40 percent.",
"     </li>",
"     <li>",
"      AV node &mdash; Supplied by the RCA in 90 percent (AV nodal branch); by the LCX in 10 percent of patients.",
"     </li>",
"     <li>",
"      His bundle &mdash; Supplied by the RCA (AV nodal branch) with a minor contribution from the septal perforators of the left anterior descending artery (LAD).",
"     </li>",
"     <li>",
"      Main or proximal left bundle branch &mdash; The LAD coronary artery provides most of the blood supply for the left bundle branch, particularly for the initial portion. There may be some collateral flow from the RCA and LCX systems.",
"     </li>",
"     <li>",
"      Left posterior fascicle &mdash; The proximal part of the left posterior fascicle is supplied by the AV nodal artery and, at times, by septal branches from the LAD. The distal portion has a dual blood supply from both anterior and posterior septal perforating arteries.",
"     </li>",
"     <li>",
"      Left anterior fascicle &mdash; The left anterior and mid-septal fascicles are supplied by septal perforators of the LAD and, in about one-half of subjects, by the AV nodal artery.",
"     </li>",
"     <li>",
"      Right bundle branch &mdash; The right bundle branch receives most of its blood supply from septal perforators from the LAD coronary artery, particularly in its initial course. It also receives some collateral supply from either the RCA or LCX coronary systems, depending upon the dominance of the coronary system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FREQUENCY OF HIGH-DEGREE BLOCK WITH ACUTE MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial data concerning the frequency of heart block after acute MI were largely derived from studies performed before the development of acute revascularization strategies in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. Reports from trials since the advent of thrombolytic therapy suggest that the incidence of intraventricular conduction disturbances (IVCDs), including bundle branch and fascicular block, during an acute MI has not changed significantly (10 to 20 percent), while the incidence of complete heart block (CHB) may be lower with thrombolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multicenter retrospective reviews",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter retrospective study prior to modern reperfusion therapies reviewed the course of 432 consecutive patients who presented to the hospital with an acute MI and a bundle branch block (BBB) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Patients with cardiogenic shock preceding the development of BBB were excluded. Because this cohort included only patients with BBB, it defines the prognostic significance but not the incidence of BBB in this setting.",
"   </p>",
"   <p>",
"    The BBB was new in 42 percent of cases, old in 21 percent, and of indeterminate age in 37 percent. This percentage of new BBB is substantially higher than that reported in other cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left bundle branch block (LBBB) was the most common, occurring in 38 percent of patients who developed an IVCD.",
"     </li>",
"     <li>",
"      Right bundle branch block (RBBB) with left anterior fascicular block (LAFB) was also common, occurring in 34 percent of patients who developed an IVCD (",
"      <a class=\"graphic graphic_waveform graphicRef69886 \" href=\"UTD.htm?29/0/29705\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      RBBB, RBBB with left posterior fascicular block (LPFB), and alternating bundle branch block occurred in 11, 10, and 6 percent of patients with new IVCD, respectively; isolated LAFB and LPFB were uncommon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ninety-five patients (22 percent) went on to develop high grade AV block defined as Mobitz type II (seven patients) or complete heart block (88 patients) (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef72863 \" href=\"UTD.htm?20/42/21160\">",
"     waveform 3",
"    </a>",
"    ). 26 of the 88 patients with CHB progressed from Mobitz type II to CHB, while the other 62 developed CHB suddenly without preceding Mobitz type II. Further analysis identified the following high risk predictors of developing CHB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New bifascicular block (RBBB plus either left anterior or left posterior fascicular block) was associated with a 31 percent risk of CHB (",
"      <a class=\"graphic graphic_waveform graphicRef69886 \" href=\"UTD.htm?29/0/29705\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New bifascicular block plus PR prolongation (trifascicular block) carried a 38 percent risk of CHB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A much larger multicenter review from the National Registry of Myocardial Infarction 2 (NRMI-2) in the United States evaluated 297,832 patients admitted to a hospital with an acute myocardial infarction between 1994 and 1997: 6.7 percent of patients had a LBBB and 6.2 percent had a RBBB on the initial ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"     17",
"    </a>",
"    ]. A similar rate of LBBB (9 percent) was noted in a prospective analysis of over 88,000 patients in Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/18\">",
"     18",
"    </a>",
"    ]. Because both of these series only assessed the presence of BBB on the initial ECG, these data provide no information on the incidence of new conduction disease in acute MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     MILIS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MILIS trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    in limiting infarct size; one report evaluated the development of CHB in patients in the study who did not receive propranolol [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/19\">",
"     19",
"    </a>",
"    ]. The incidence of new CHB was 5.4 percent, occurring a mean of 2.6 days after MI. CHB developed more frequently in patients older than 60 and in those with significant heart failure. Nineteen percent of patients with CHB also developed cardiogenic shock.",
"   </p>",
"   <p>",
"    A risk score was developed from the MILIS data to predict the development of CHB. One point was assigned for the new development of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PR prolongation",
"     </li>",
"     <li>",
"      Second degree AV block",
"     </li>",
"     <li>",
"      Left anterior or posterior fascicular block",
"     </li>",
"     <li>",
"      LBBB",
"     </li>",
"     <li>",
"      RBBB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of progression to CHB was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.2 to 6.8 percent with a point score of 0.",
"     </li>",
"     <li>",
"      7.8 to 10 percent with a score of 1.",
"     </li>",
"     <li>",
"      25 to 30 percent with a score of 2.",
"     </li>",
"     <li>",
"      36 percent with a score of 3 or more.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of developing CHB in this report was not associated with infarct location or left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    The MILIS scoring system was then applied to six previously published studies of acute MI complicated by CHB. A similar incremental risk of developing CHB was seen in these studies as that noted in the original MILIS data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thrombolysis trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest experience with high degree AV block in the thrombolytic era comes from a review of almost 76,000 patients with ST elevation MI enrolled in four large randomized trials of thrombolytic therapy (GUSTO-I, GUSTO-III, ASSENT-II, and GUSTO-IIb) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"     20",
"    </a>",
"    ]. The overall incidence of high degree AV block was 6.9 percent: 9.8 percent with inferior MI and 3.2 percent with anterior MI.",
"   </p>",
"   <p>",
"    The available data suggest that the incidence of CHB in acute MI may be somewhat lower with thrombolytic therapy: CHB in 4 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/2,21-24\">",
"     2,21-24",
"    </a>",
"    ]; and the combined end-point of CHB or second degree AV block in 7 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. In an analysis of survey data on thrombolysis in Israel, the incidence of CHB during the 1990s (since the advent of thrombolysis) was significantly lower than during the 1980s (3.7 versus 5.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/2\">",
"     2",
"    </a>",
"    ]. A similar rate in the prethrombolysis era (5.8 percent) was noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data regarding the incidence of bundle branch block (BBB) in patients with an acute MI treated with thrombolytic agents; however, data suggest that the incidence has",
"    <strong>",
"     not",
"    </strong>",
"    been altered by reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. One study evaluated 681 patients from one institution entered into the TAMI 9 or GUSTO-1 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/25\">",
"     25",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of transient BBB was 18.4 percent, while persistent BBB occurred in 5.3 percent of patients.",
"     </li>",
"     <li>",
"      BBB was associated with lower ejection fractions, larger infarctions, and more diseased vessels.",
"     </li>",
"     <li>",
"      RBBB was most common (occurring in 13 percent of patients) followed by LBBB (7 percent), and alternating bundle branch block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another analysis, a substudy of the TRACE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    in acute MI evaluated 6657 patients, 41 percent of whom received thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/26\">",
"     26",
"    </a>",
"    ]. Complete heart block occurred in 340 (5.1 percent) and BBB in 533 (8.0 percent). Of those who developed complete heart block, the onset occurred within the first two days after MI in 81 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports that have assessed the incidence and prognostic significance of high degree AV block after MI have not distinguished between ST elevation (Q wave) MI (STEMI) and non-ST elevation (non-Q wave) MI (NSTEMI). One study from the SPRINT study group reported on 610 patients with a first NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/27\">",
"     27",
"    </a>",
"    ]. Second or third degree AV block developed in 45 patients (7 percent). Compared to patients without AV block, these patients had a higher rate of cardiac arrest, heart failure, elevation of cardiac enzymes, and in-hospital mortality, but there was no difference in one or five year mortality. These findings suggest that high degree AV block in patients with NSTEMI is associated with larger and more complicated infarctions, as is the case in patients with an STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to high degree AV block after MI in older adults are similar to those in younger patients. In a review of over 100,000 infarcts in Medicare beneficiaries, high degree AV block occurred in 4.7 percent overall; the AV block was new in 3.2 percent and was more common with inferior compared to anterior infarcts (7.3 versus 3.0 percent), especially with inferior infarcts treated with thrombolysis (8.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/28\">",
"     28",
"    </a>",
"    ]. After adjustment for risk factors, heart block was associated with increased risk of in-hospital mortality (relative risk 1.41) but, among hospital survivors, no difference in one-year mortality (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Mortality and heart blocks'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONDUCTION DISTURBANCES AND INFARCT LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical management of patients with bradyarrhythmias or conduction abnormalities after an MI depends in part upon the location of the infarct. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Management of heart block'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High (second or third) degree AV block associated with inferior wall MI is located",
"      <strong>",
"       above",
"      </strong>",
"      the His bundle in 90 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/8,29\">",
"       8,29",
"      </a>",
"      ]. For this reason, complete heart block often results in only a modest and usually transient bradycardia with junctional or escape rhythm rates above 40 beats per minute. It is not uncommon, however, for the junctional pacemaker that controls the ventricles to accelerate above 60",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      The QRS is narrow in this setting and is associated with a low mortality.",
"     </li>",
"     <li>",
"      High degree AV block associated with anterior MI is more often located",
"      <strong>",
"       below",
"      </strong>",
"      the AV node [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/8\">",
"       8",
"      </a>",
"      ]. It is usually symptomatic and has been associated with a mortality rate approaching 80 percent due in large part to greater loss of functioning myocardium. The current mortality may be somewhat less due to improvements in the management of congestive heart failure and cardiogenic shock, but the risk remains substantial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Inferior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction disturbance in inferior MI can occur acutely or after hours or days. Sinus bradycardia, Mobitz type I (Wenckebach), and complete heart block are commonly seen, since the SA node, AV node, and His bundle are primarily supplied by the RCA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia &mdash; Sinus bradycardia is the most common arrhythmia associated with inferior MI. It is present in up to 40 percent of patients in the first two hours, decreasing to 20 percent by the end of the first day. It is usually attributable to increased vagal tone in the first 24 hours after infarction. Transient sinus node dysfunction occurring later may be due to sinus node or atrial ischemia.",
"     </li>",
"     <li>",
"      First degree AV block (prolonged A-V conduction) &mdash; First degree AV block (characterized by prolongation of the PR interval) can arise in the AV node, the bundle of His, or the bundle branches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link\">",
"       \"First degree atrioventricular block\"",
"      </a>",
"      .) First degree AV block at the level of the AV node is common after occlusion of the coronary artery which gives rise to the AV nodal artery and the arteries to the inferior and posterior wall of the heart (most often the RCA). RCA occlusion can lead to first degree AV block via ischemia of the AV node, by enhanced acetylcholine release from the inferoposterior myocardium, or perhaps by making the AV node hypersensitive to the action of acetylcholine. First degree AV block due to occlusion of the RCA with involvement of the AV node is usually transient, generally resolving in five to seven days and requiring no therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occlusion of the left circumflex artery may affect the AV node directly in the 10 percent of individuals in whom it supplies the AV node. Less commonly, anterior MI produces first degree AV block",
"    <strong>",
"     below",
"    </strong>",
"    the level of the AV node, a situation that should be suspected if first degree AV block occurs in the presence of a widened QRS complex.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High degree AV block &mdash; High (second or third) degree AV block occurs in approximately 9.8 percent of patients with an inferior MI who receive thrombolytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"       20",
"      </a>",
"      ]. Approximately one-half of cases are present on admission and one-half develop in the 24 hours after thrombolytic therapy is given [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inferior MI is typically associated with the more benign second degree AV block of the Wenckebach type (Mobitz type 1) (",
"    <a class=\"graphic graphic_waveform graphicRef73051 graphicRef62040 \" href=\"UTD.htm?3/23/3450\">",
"     waveform 4A-B",
"    </a>",
"    ); Mobitz type II is uncommon in this setting, generally occurring with anterior MI (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanism is similar to that described above for first degree AV block. Mobitz type I block is usually transient, resolving in most cases within five days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, RCA occlusion produces complete heart block that is usually transient but may persist. The latter finding suggests concurrent involvement of the left coronary system, resulting in poor collateral flow.",
"   </p>",
"   <p>",
"    CHB with inferior MI generally results from an intranodal lesion. It is associated with a narrow QRS complex, and develops in a progressive fashion from first to second to third degree block. It often results in an asymptomatic bradycardia (40 to 60",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    and is usually transient, resolving within five to seven days. In the substudy from the TRACE trial described above, the incidence of CHB was significantly higher among patients with an inferior MI than among those with an anterior MI (9.4 versus 2.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/26\">",
"     26",
"    </a>",
"    ]. A similar difference (7.7 versus 3.9 percent) was noted in a report in the prethrombolytic era [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anterior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious conduction disturbances more commonly occur with anteroseptal MI, and the degree of arrhythmic complications is usually directly related to the extent of infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First degree AV block &mdash; Prolongation of the PR interval due to slowed AV nodal conduction is an uncommon complication of anterior MI, since the AV node is usually supplied by the RCA. However, AV nodal conduction delay can occur in the 10 percent of individuals in whom the AV node is supplied by the left circumflex artery, in the presence of severe multivessel disease in which collaterals to the RCA may be compromised, and in elderly patients with preexisting conduction disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More often, first degree AV block in anterior MI is due to involvement of the conducting system below the level of the AV node. In this setting, there is usually widening of the QRS complex beyond 0.12 sec.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High degree AV block &mdash; High (second or third) degree AV block occurs in approximately 3.2 percent of patients with an anterior MI who receive thrombolytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"       20",
"      </a>",
"      ]. Second degree AV block with anterior MI is usually at the level of the AV node or below and is almost exclusively a Mobitz type II block. The clinical course may be unpredictable, with CHB developing with little warning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type II\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AV nodal Wenckebach can occur with occlusion of the left circumflex artery in the 10 percent of individuals whose AV node is supplied by this artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CHB with anterior MI generally occurs abruptly in the first 24 hours. It can develop without warning or may be preceded by the development of RBBB with either a LAFB or LPFB (bifascicular or trifascicular block) (",
"    <a class=\"graphic graphic_waveform graphicRef69886 \" href=\"UTD.htm?29/0/29705\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/13\">",
"     13",
"    </a>",
"    ]. The escape rhythm is wide and unstable and the event is associated with a high mortality (approximately 80 percent) from both arrhythmias and pump failure. Heart block in this setting is thought to result from extensive necrosis that involves the bundle branches traveling within the septum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the substudy from the TRACE trial described above, the incidence of CHB was significantly lower among patients with an anterior MI than among those with an inferior MI (2.5 versus 9.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/26\">",
"     26",
"    </a>",
"    ]. A similar difference (3.9 versus 7.7 percent) was noted in a report in the prethrombolytic era [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MORTALITY AND HEART BLOCKS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     High degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;High (second or third) degree AV block is associated with an increase in mortality in patients with an inferior or anterior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/12,20,26\">",
"     12,20,26",
"    </a>",
"    ]. The increase in mortality risk is largely seen within the first 30 days; among 30-day survivors, subsequent mortality does not appear to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20,26\">",
"     20,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although high grade AV block in patients with an inferior MI is usually transient, it is associated with increased in-hospital mortality. In the prethrombolytic era, the average mortality was 9 percent without AV block compared to 23 and 29 percent when second and third degree AV block were present, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in mortality with high degree AV block is still apparent in patients with an inferior MI treated with a thrombolytic agent, [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/2,12,20,26,30,34,35\">",
"     2,12,20,26,30,34,35",
"    </a>",
"    ]. The largest experience comes from the review of almost 76,000 patients enrolled in four large randomized trials of thrombolytic therapy cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"     20",
"    </a>",
"    ]. Among patients with an inferior MI, the 9.8 percent with high degree AV block had a significant and substantial increase in mortality at 30 days (15 versus 4 percent in those without AV block; odds ratio 2.2, 95% CI 1.7-2.7). The increase in mortality did not increase further at one year.",
"   </p>",
"   <p>",
"    High degree AV block in patients with an anterior wall myocardial infarction is associated with a greater increase in in-hospital and 30-day mortality than seen with an inferior wall infarction, probably due to more extensive myocardial involvement and a higher incidence of hemodynamic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. The magnitude of this effect was illustrated in the review of four randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"     20",
"    </a>",
"    ]. Among patients with an anterior MI, the 3.2 percent with AV block had a significant and substantial increase in mortality at 30 days (41 versus 8 percent in those without AV block; odds ratio 3.0, 95% CI 2.2-4.1). The increase in mortality did not increase further at one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fascicular or bundle branch block (BBB) during an acute MI is associated with an increase in in-hospital and long-term mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3,9,13-18,36-39\">",
"     3,9,13-18,36-39",
"    </a>",
"    ]. However, interpreting the prognostic significance of BBB is complicated for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to CHB, which is almost always a new finding due to the MI, BBB often precedes the MI. In the HERO-2 trial, discussed below, BBB was present of 5.1 percent of initial ECGs, but new BBB developed in only 0.9 percent of patients on a second ECG taken 60 minutes later [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"       3",
"      </a>",
"      ]. Reports from case series and registries generally define the presence of BBB on the basis of the initial ECG. This finding reflects the prevalence of BBB among patients presenting with acute MI, not the incidence of new BBB due to the infarction. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'New versus chronic BBB'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Chronic and new conduction abnormalities may both predict poorer outcomes, but for different reasons. The former due to more extensive underlying cardiac disease and the latter due to the association with larger infarctions.",
"     </li>",
"     <li>",
"      Post-hoc analyses of primary reperfusion trials are limited by selection bias, because BBB, particularly LBBB, is often an exclusion criterion for enrollment in these trials.",
"     </li>",
"     <li>",
"      In clinical practice, the diagnosis of acute MI may be hindered by the presence of BBB, particularly LBBB. This may introduce bias to the inclusion of patients in large registries.",
"     </li>",
"     <li>",
"      Patients with BBB may be less likely to receive standard therapy, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and beta-blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings in large groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression to second or third degree AV block is associated with twice the in-hospital mortality compared to those who do not progress [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the NRMI-2 review, 12.9 percent of almost 300,000 patients had LBBB or RBBB [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"       17",
"      </a>",
"      ]. The unadjusted in-hospital mortality was 22.6 and 23.0 percent with LBBB and RBBB, respectively, compared to 13.1 percent in patients with no BBB.",
"     </li>",
"     <li>",
"      In an analysis of 26,003 North American patients entered into the GUSTO-I trial of thrombolytic therapy, the in-hospital mortality was 18 versus 11 percent with and without a BBB [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients with a BBB were more likely to experience cardiogenic shock (19 versus 11 percent), AV block or asystole (30 versus 19 percent), and to require a pacemaker (18 versus 11 percent). Mortality was higher when the BBB was persistent (20 percent versus 12 and 8 percent in the 24 percent of patients who had partial or complete resolution of the BBB, respectively).",
"     </li>",
"     <li>",
"      Among patients undergoing primary percutaneous coronary intervention, the presence of BBB on the baseline electrocardiogram is associated with increased mortality. This was illustrated in a review of 3053 patients in the PAMI trials; LBBB was present in 1.6 percent and RBBB in 3.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/37\">",
"       37",
"      </a>",
"      ]. In-hospital mortality was 14.6, 7.4, and 2.8 percent in patients with LBBB, RBBB, and no BBB, respectively. On multivariate analysis, LBBB was an independent predictor of in-hospital mortality (odds ratio 5.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies largely made the assessment of the presence or absence of BBB on the initial ECG. Thus, it could not be determined whether the BBB was preexisting or associated with the infarction unless there was resolution of the BBB.",
"   </p>",
"   <p>",
"    A post hoc analysis of over 17,000 patients from the HERO-2 trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    versus unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was able to assess the significance of new BBB since ECGs were obtained before and 60 minutes after the start of thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"     3",
"    </a>",
"    ]. BBB was present at baseline in 873 patients (5.1 percent) and developed within 60 minutes in 143 (0.9 percent). Among the 143 patients with new BBB, 25 had LBBB and 118 had RBBB. RBBB occurred in association with an anterior MI in 100 patients, while the association of LBBB with infarct location was not reported.",
"   </p>",
"   <p>",
"    After adjustment for baseline characteristics, 30-day mortality was significantly increased only in patients with RBBB at baseline and an anterior MI (odds ratio 2.48) and in those with new LBBB (odds ratio 2.97) or new RBBB with an anterior MI (odds ratio 3.84). The increase in risk with RBBB and an anterior MI has been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Increased comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BBB have more comorbidities and are less likely to receive appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. This was illustrated in the NRMI-2 review in which the patients with BBB compared to those without BBB were older, more likely to have a history of hypertension, diabetes, and stroke, and more frequently had heart failure, a prior infarction, or bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"     17",
"    </a>",
"    ]. Fewer patients with BBB who did not have a contraindication to thrombolytics received this therapy (17 and 32 percent for LBBB and RBBB, respectively, compared to 67 percent of those without a BBB) and fewer with LBBB or RBBB received a beta blocker within the first 24 hours (24 and 32 versus 40 percent). Patients with permanent pacemakers are also less likely to receive reperfusion therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After adjustment for potential confounders in NRMI-2, LBBB and RBBB were still associated with a significant 34 and 64 percent increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, in a Swedish study, adjustment for differences in age, baseline characteristics, concomitant diseases, acute therapy, and left ventricular ejection fraction eliminated the increase in mortality at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/18\">",
"     18",
"    </a>",
"    ]. Similarly, the increase in mortality was no longer significant after adjustment for baseline characteristics in patients in HERO-2 who had LBBB at presentation or RBBB with an inferior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     New versus chronic BBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the prognostic significance of LBBB is complicated by uncertainty regarding the age of a LBBB that is noted on an initial ECG. In the HERO-2 trial described below, 300 patients were enrolled with a presumed new LBBB on the initial ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/41\">",
"     41",
"    </a>",
"    ]. In a separate report from the same cohort, it was noted that an additional 25 patients developed LBBB on a follow-up ECG 60 minutes later [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"     3",
"    </a>",
"    ]. There was a large discrepancy in outcomes between these two groups. Adjusted 30 day mortality rates, compared to controls with normal conduction, were lower in patients with LBBB at presentation, but higher in those who developed LBBB in the first 60 minutes (adjusted OR 0.68 and 2.97 respectively).",
"   </p>",
"   <p>",
"    A possible explanation for this discrepancy is that many of the patients with presumed new LBBB at presentation actually had chronic LBBB. Thus, truly new LBBB would be much less common (eg, 0.15 percent developed LBBB between the first and second ECG), but carries a substantially worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     ST segment changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute MI and LBBB who also have ST segment changes may have an increased mortality risk. This was illustrated in a review of 17,073 patients with acute MI from the HERO-2 trial, which compared outcomes among 300 patients with presumed new LBBB at presentation to those of 15,340 patients with normal intraventricular conduction; all patients received thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with LBBB tended to be older and have more comorbidities; as a result, a separate analysis compared outcomes among the patients with LBBB to patients with normal intraventricular conduction who were matched for age and comorbidities.",
"   </p>",
"   <p>",
"    Among the 300 patients with LBBB, 92 (31 percent) had concordant ST elevation &ge;1 mm in any lead or ST depression &ge;1 mm in any lead V1 to V3. These two abnormalities are the major Sgarbossa criteria that are used to assist in the diagnosis of acute MI in patients with LBBB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link&amp;anchor=H9#H9\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\", section on 'Sgarbossa criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with LBBB had a significantly higher 30-day mortality rate than the entire population (ie, not only matched controls) (16 versus 9 percent).",
"     </li>",
"     <li>",
"      When the patients with LBBB were compared to matched controls, the outcomes were affected by the presence or absence of ST changes. Patients with LBBB and ST changes had similar 30-day mortality to matched controls with normal intraventricular conduction (21.7 versus 25 percent), while those with LBBB and no ST changes had a significantly lower mortality than matched controls (13.5 versus 21.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, among the patients with LBBB, there was a nonsignificant increase in 30-day mortality in those patients with ST changes (21.7 versus 13.5 percent with no ST changes, p = 0.07).",
"   </p>",
"   <p>",
"    Similar results were reported in an analysis from the ASSENT 2 and 3 trials, which compared different thrombolysis regimens for acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/42\">",
"     42",
"    </a>",
"    ]. Compared to patients without LBBB, adjusted one year mortality was significantly higher in patients with LBBB and a Sgarbossa score &ge;3, but not in those with LBBB and a Sgarbossa score &lt;3 (adjusted OR 3.8 and 0.9, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link&amp;anchor=H9#H9\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\", section on 'Sgarbossa criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Distant prior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the prognostic significance of BBB in patients who have had a distant prior MI. This issue was addressed in the MUSTT trial and registry of patients who had a prior MI less than one month to more than three years previously [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/43\">",
"     43",
"    </a>",
"    ]. Among 1638 patients who did not receive antiarrhythmic drugs or an implantable cardioverter-defibrillator, LBBB and intraventricular conduction delay were each associated with a 50 percent increase in arrhythmic and total mortality. In contrast, there was no increase in mortality in patients with RBBB. Similar findings were noted in the CASS registry of patients with chronic CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HEART BLOCK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Use of atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias that occur early in the setting of an inferior MI (within the first 24 hours) may respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , while those occurring later are often atropine-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/8,29\">",
"     8,29",
"    </a>",
"    ]. Treatment is not indicated in asymptomatic patients, but is useful if symptoms are present such as dizziness, syncope, or confusion from reduced cardiac output. Atropine is administered in 0.5 mg or 1 mg increments to a total of 3 mg. Caution should be used with administering atropine in the setting of active ischemia because precipitation of ventricular fibrillation has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/45\">",
"     45",
"    </a>",
"    ]. Refractory hypotension after correction of the bradycardia with atropine usually indicates volume depletion or concurrent right ventricular infarction. Volume infusion is the treatment of choice in this setting. A task force of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association has published guidelines for the use of atropine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Use of cardiac pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The point system described above (see",
"    <a class=\"local\" href=\"#H9\">",
"     'MILIS trial'",
"    </a>",
"    above) can be useful in deciding which patients might benefit most from cardiac pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients with two or more of the following new findings are at 25 to 36 percent risk of progression to CHB: PR prolongation, second degree AV block, left anterior or posterior fascicular block, LBBB, and RBBB.",
"   </p>",
"   <p>",
"    Guidelines for the implantation of cardiac pacemakers were published in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/46\">",
"     46",
"    </a>",
"    ]; pacing was also addressed in the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with acute STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/1\">",
"     1",
"    </a>",
"    ]. No changes were made in the recommendations were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Indications for temporary transvenous pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary transvenous pacing is necessary for patients with severe and symptomatic bradyarrhythmias, but should also be considered in those at high risk of developing CHB as a consequence of acute MI. Due to the dynamic and potentially progressive nature of conduction abnormalities in the setting of an acute MI, unique indications for temporary pacing have been defined. Detailed discussion of the indications for temporary pacing are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link&amp;anchor=H18#H18\">",
"     \"Temporary cardiac pacing\", section on 'Temporary pacing in acute myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations regarding temporary pacing in the setting of acute MI were included in the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Guidelines for the management of patients with ST elevation myocardial infarction&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/1\">",
"     1",
"    </a>",
"    ]. No changes in the recommendations were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When temporary pacing is required, we recommend transvenous pacing. We do not favor the use of the external temporary cardiac pacer because of the physical discomfort associated with external pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Standard indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider temporary transvenous pacing in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete (third-degree) heart block.",
"     </li>",
"     <li>",
"      Alternating right and left BBB, or RBBB with alternating LAFB or LPFB.",
"     </li>",
"     <li>",
"      New or age indeterminate bifascicular block (RBBB with LAFB or LPFB or LBBB) with PR prolongation.",
"     </li>",
"     <li>",
"      Asystole.",
"     </li>",
"     <li>",
"      Symptomatic bradycardia of any etiology, including sinus bradycardia and Mobitz type I second degree AV block, if hypotension is present and the bradyarrhythmia is not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Mobitz type II second-degree AV block.",
"     </li>",
"     <li>",
"      Bradycardia-induced tachyarrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary transvenous pacing may also be appropriate in other situations. In these cases, the decision to place a temporary pacemaker is based upon the nature of the conduction disorder, the location of the infarction, and associated symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inferior infarction &mdash; In patients with inferior infarction, complete heart block may be transient and hemodynamically tolerated. We do not routinely insert a pacemaker for CHB if the escape rhythm has a narrow QRS and an adequate ventricular rate, because this junctional rhythm is usually stable. However, careful monitoring is mandatory and we have a low threshold for pacing given the potential for rapid deterioration.",
"     </li>",
"     <li>",
"      Right ventricular infarction &mdash; Indications for pacing in right ventricular infarction are discussed separately. Bradyarrhythmias can significantly worsen the hemodynamic status in such patients since the ischemic right ventricle has a relatively fixed stroke volume and is therefore dependent upon heart rate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New BBB &mdash; As noted in the HERO-2 report, new BBB complicating acute MI is rare (0.73 and 0.15 percent of patients developed RBBB and LBBB respectively in the first 60 minutes after presentation) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"       3",
"      </a>",
"      ]. New BBB was associated with substantial short term mortality, particularly in the setting of an anterior MI (&gt;30 percent at 30 days). However, the incidence of progressive conduction disease (ie, CHB) and its contribution to poor outcomes is not known, and therefore the potential benefit of prophylactic temporary pacing in this setting is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Indications for permanent pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for permanent pacemaker placement following acute MI are included in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/46\">",
"     46",
"    </a>",
"    ], and the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of acute STEMI (",
"    <a class=\"graphic graphic_table graphicRef61413 \" href=\"UTD.htm?16/41/17052\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/1\">",
"     1",
"    </a>",
"    ]. No changes in the recommendations were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for permanent pacing, including those related to patients after a myocardial infarction, are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H15#H15\">",
"     \"Indications for permanent cardiac pacing\", section on 'Post myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Implantable cardioverter-defibrillator",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of indications for implantable cardioverter-defibrillator (ICD) therapy after an MI. These include secondary prevention for patients with hemodynamically significant ventricular tachycardia or ventricular fibrillation more than 48 hours post-MI, and for primary prevention in patients meeting certain specific indications. These indications are discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended that all patients who have an indication for permanent pacing after MI should be evaluated to determine if an ICD is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/11/4282/abstract/1\">",
"     1",
"    </a>",
"    ]. However, current Medicare guidelines stipulate that ICD implantation will be reimbursed only for those patients who meet criteria 40 days after the MI. We suggest that patients who require implantation of a permanent pacemaker prior to 40 days after an infarction and also meet criteria for an ICD should be treated with an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cardiac resynchronization therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) with biventricular pacing may be appropriate for selected patients after an MI. Ventricular dyssynchrony refers to the loss of coordinated contraction across the left ventricle. Dyssynchrony can further impair the pump function of a failing ventricle and exacerbate heart failure symptoms. Dyssynchrony often develops in patients with significant conduction system disease and QRS prolongation, and a similar phenomenon may develop with RV pacing, which can mimic the effects of LBBB.",
"   </p>",
"   <p>",
"    CRT can improve pump performance, reverse the deleterious process of ventricular remodeling, and improve survival in appropriately selected patients. The indications of CRT are discussed separately. It is reasonable to evaluate all patients who have an indication for permanent pacing after an MI for CRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;AV synchrony &mdash; For patients in sinus rhythm, dual chamber pacing offers several potential physiologic advantages over single chamber pacemakers, including higher cardiac output and arterial pressure, reduced incidence of \"pacemaker syndrome,\" and reduced frequency of AF. In patients with chronic AF, atrial synchronous pacing is not feasible, and a ventricular pacing system is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Managed ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DAVID trial in patients with left ventricular dysfunction and the MOST trial in patients with sinus node dysfunction both demonstrated that frequent pacing using a single ventricular pacing lead can lead to an increased incidence of heart failure, an effect that has been attributed to the creation of interventricular dyssynchrony. These studies suggest that, when antibradycardia pacing is instituted, it is appropriate to consider the potential benefit of CRT (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Cardiac resynchronization therapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Alternatively, for patients with transient AV conduction abnormalities, pacemakers are now available that minimize ventricular pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H13#H13\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Modes to minimize ventricular pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1835839983\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias and conduction disturbances are well-recognized complications of acute myocardial infarction (MI). They are caused by either autonomic imbalance or",
"    <span class=\"nowrap\">",
"     ischemia/necrosis",
"    </span>",
"    of the conduction system. The following points constitute the basis of recommendations for the use of temporary transvenous pacing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete heart block (CHB) with inferior MI generally results from an intranodal lesion. It is associated with a narrow QRS complex, and develops in a progressive fashion from first to second to third degree block. It often results in an asymptomatic bradycardia (40 to 60",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      and is usually transient, resolving within five to seven days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Inferior MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CHB with anterior MI generally occurs abruptly in the first 24 hours. It can develop without warning or may be preceded by the development of right bundle branch block (RBBB) with either a left anterior or posterior fascicular block pattern (bifascicular or trifascicular block). The escape rhythm is wide and unstable and the event is associated with a high mortality (approximately 80 percent) from both arrhythmias and pump failure. Heart block in this setting is thought to result from extensive necrosis that involves the bundle branches traveling within the septum. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anterior MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-degree atrioventricular block in patients with an anterior wall myocardial infarction is associated with a greater increase in in-hospital and 30-day mortality than seen with an inferior wall infarction, probably due to more extensive myocardial involvement and a higher incidence of hemodynamic complications. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anterior MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradyarrhythmias that occur early in the setting of an inferior MI (within the first 24 hours) may respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , while those occurring later are often atropine-resistant. Treatment is not indicated in asymptomatic patients, but is useful if symptoms are present, such as dizziness, syncope, or confusion from reduced cardiac output. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Inferior MI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider temporary transvenous pacing in the following circumstances (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Indications for temporary transvenous pacing'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete (third-degree) heart block.",
"     </li>",
"     <li>",
"      Alternating right and left bundle branch block.",
"     </li>",
"     <li>",
"      RBBB with alternating left anterior or posterior fascicular block.",
"     </li>",
"     <li>",
"      New or age indeterminate bifascicular block (RBBB with left anterior or posterior fascicular block or left bundle branch block) with PR prolongation.",
"     </li>",
"     <li>",
"      Asystole.",
"     </li>",
"     <li>",
"      Symptomatic bradycardia of any etiology, including sinus bradycardia and Mobitz type I second degree AV block, if hypotension is present and the bradyarrhythmia is not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Mobitz type II second-degree AV block.",
"     </li>",
"     <li>",
"      Bradycardia-induced tachyarrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/2\">",
"      Harpaz D, Behar S, Gottlieb S, et al. Complete atrioventricular block complicating acute myocardial infarction in the thrombolytic era. SPRINT Study Group and the Israeli Thrombolytic Survey Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Am Coll Cardiol 1999; 34:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/3\">",
"      Wong CK, Stewart RA, Gao W, et al. Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Eur Heart J 2006; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenbaum M, Elizari MV, Lazzari JO. The Hemiblocks. Tampa Tracings, Tampa, 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/5\">",
"      Uhley HN. Some controversy regarding the peripheral distribution of the conduction system. Am J Cardiol 1972; 30:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/6\">",
"      Hecht HH, Kossmann CE, Childers RW, et al. Atrioventricular and intraventricular conduction. Revised nomenclature and concepts. Am J Cardiol 1973; 31:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/7\">",
"      Demoulin JC, Kulbertus HE. Histopathological examination of concept of left hemiblock. Br Heart J 1972; 34:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/8\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/9\">",
"      Godman MJ, Lassers BW, Julian DG. Complete bundle-branch block complicating acute myocardial infarction. N Engl J Med 1970; 282:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/10\">",
"      Gupta PK, Lichstein E, Chadda KD. Heart block complicating acute inferior wall myocardial infarction. Chest 1976; 69:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/11\">",
"      Sugiura T, Iwasaka T, Hasegawa T, et al. Factors associated with persistent and transient fascicular blocks in anterior wall acute myocardial infarction. Am J Cardiol 1989; 63:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/12\">",
"      Goldberg RJ, Zevallos JC, Yarzebski J, et al. Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart Attack Study). Am J Cardiol 1992; 69:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/13\">",
"      Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation 1978; 58:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/14\">",
"      Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation 1978; 58:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/15\">",
"      Scheinman MM, Gonzalez RP. Fascicular block and acute myocardial infarction. JAMA 1980; 244:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/16\">",
"      Dubois C, Pi&eacute;rard LA, Smeets JP, et al. Short- and long-term prognostic importance of complete bundle-branch block complicating acute myocardial infarction. Clin Cardiol 1988; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/17\">",
"      Go AS, Barron HV, Rundle AC, et al. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med 1998; 129:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/18\">",
"      Stenestrand U, Tabrizi F, Lindb&auml;ck J, et al. Comorbidity and myocardial dysfunction are the main explanations for the higher 1-year mortality in acute myocardial infarction with left bundle-branch block. Circulation 2004; 110:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/19\">",
"      Lamas GA, Muller JE, Turi ZG, et al. A simplified method to predict occurrence of complete heart block during acute myocardial infarction. Am J Cardiol 1986; 57:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/20\">",
"      Meine TJ, Al-Khatib SM, Alexander JH, et al. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. Am Heart J 2005; 149:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/21\">",
"      GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990; 336:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/22\">",
"      Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/23\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/24\">",
"      Archbold RA, Sayer JW, Ray S, et al. Frequency and prognostic implications of conduction defects in acute myocardial infarction since the introduction of thrombolytic therapy. Eur Heart J 1998; 19:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/25\">",
"      Newby KH, Pisan&oacute; E, Krucoff MW, et al. Incidence and clinical relevance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. Circulation 1996; 94:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/26\">",
"      Aplin M, Engstr&oslash;m T, Vejlstrup NG, et al. Prognostic importance of complete atrioventricular block complicating acute myocardial infarction. Am J Cardiol 2003; 92:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/27\">",
"      Haim M, Hod H, Kaplinsky E, et al. Frequency and prognostic significance of high-degree atrioventricular block in patients with a first non-Q-wave acute myocardial infarction. The SPRINT Study Group. Second Prevention Reinfarction Israeli Nifedipine Trial. Am J Cardiol 1997; 79:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/28\">",
"      Rathore SS, Gersh BJ, Berger PB, et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. Am Heart J 2001; 141:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/29\">",
"      Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol 1984; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/30\">",
"      Berger PB, Ruocco NA Jr, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 1992; 20:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/31\">",
"      Berger PB, Ryan TJ. Inferior myocardial infarction. High-risk subgroups. Circulation 1990; 81:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/32\">",
"      Nicod P, Gilpin E, Dittrich H, et al. Long-term outcome in patients with inferior myocardial infarction and complete atrioventricular block. J Am Coll Cardiol 1988; 12:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/33\">",
"      Behar S, Zissman E, Zion M, et al. Complete atrioventricular block complicating inferior acute wall myocardial infarction: short- and long-term prognosis. Am Heart J 1993; 125:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/34\">",
"      Clemmensen P, Bates ER, Califf RM, et al. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. Am J Cardiol 1991; 67:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/35\">",
"      Abidov A, Kaluski E, Hod H, et al. Influence of conduction disturbances on clinical outcome in patients with acute myocardial infarction receiving thrombolysis (results from the ARGAMI-2 study). Am J Cardiol 2004; 93:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/36\">",
"      Sgarbossa EB, Pinski SL, Topol EJ, et al. Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/37\">",
"      Guerrero M, Harjai K, Stone GW, et al. Comparison of the prognostic effect of left versus right versus no bundle branch block on presenting electrocardiogram in acute myocardial infarction patients treated with primary angioplasty in the primary angioplasty in myocardial infarction trials. Am J Cardiol 2005; 96:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/38\">",
"      Ricou F, Nicod P, Gilpin E, et al. Influence of right bundle branch block on short- and long-term survival after acute anterior myocardial infarction. J Am Coll Cardiol 1991; 17:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/39\">",
"      Brilakis ES, Wright RS, Kopecky SL, et al. Bundle branch block as a predictor of long-term survival after acute myocardial infarction. Am J Cardiol 2001; 88:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/40\">",
"      Rathore SS, Weinfurt KP, Gersh BJ, et al. Treatment of patients with myocardial infarction who present with a paced rhythm. Ann Intern Med 2001; 134:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/41\">",
"      Wong CK, French JK, Aylward PE, et al. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. J Am Coll Cardiol 2005; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/42\">",
"      Al-Faleh H, Fu Y, Wagner G, et al. Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. Am Heart J 2006; 151:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/43\">",
"      Zimetbaum PJ, Buxton AE, Batsford W, et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation 2004; 110:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/44\">",
"      Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol 1987; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/45\">",
"      Cooper MJ, Abinader EG. Atropine-induced ventricular fibrillation: case report and review of the literature. Am Heart J 1979; 97:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/11/4282/abstract/46\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 45 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4282=[""].join("\n");
var outline_f4_11_4282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1835839983\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Issues related to LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations of incidence and prognosis data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY AND BLOOD SUPPLY OF THE CONDUCTION SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FREQUENCY OF HIGH-DEGREE BLOCK WITH ACUTE MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multicenter retrospective reviews",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MILIS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thrombolysis trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONDUCTION DISTURBANCES AND INFARCT LOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Inferior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anterior MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MORTALITY AND HEART BLOCKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      High degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Increased comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - New versus chronic BBB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - ST segment changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Distant prior MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT OF HEART BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Use of atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Use of cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Indications for temporary transvenous pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Standard indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Indications for permanent pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Managed ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1835839983\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/45\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/45|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/52/43841\" title=\"figure 1\">",
"      Normal conduction system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/44/22213\" title=\"figure 2\">",
"      Coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/45|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/41/17052\" title=\"table 1\">",
"      ACC AHA HRS pacing acute MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/45|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/0/29705\" title=\"waveform 1\">",
"      ECG RBBB LAFB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29270\" title=\"waveform 2\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/42/21160\" title=\"waveform 3\">",
"      ECG third degree or complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 4A\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/7/6262\" title=\"waveform 4B\">",
"      ECG Mobitz type I AV block and inferior MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_11_4283="Alarm signs and symptoms in a patient with excessive flatulence";
var content_f4_11_4283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alarm signs and symptoms requiring work-up in a patient with excessive flatulence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Nocturnal abdominal pain (sleep awakening)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood in the stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severely tender abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Succussion splash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New onset diarrhea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4283=[""].join("\n");
var outline_f4_11_4283=null;
var title_f4_11_4284="Monoclonal Ab Nomenclature";
var content_f4_11_4284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monoclonal antibodies: Guidelines for nomenclature",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The following letters were approved as product source identifiers:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        u = human",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        o = mouse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a = rat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        e = hamster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        i = primate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        xi = chimeric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        These identifiers are used as infixes preceding the -mab suffix stem:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -umab (human)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -omab (mouse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -ximab (chimeric)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -zumab (humanized)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disease or target class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral = vir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial = bac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune = lim",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious lesions = les",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular = cir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon = col",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanoma = mel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mammary = mar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testis = got",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovary = gov",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate = pr(o)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous = tum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Available online at: www.ama-assn.org/ama/pub/category/13280.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4284=[""].join("\n");
var outline_f4_11_4284=null;
var title_f4_11_4285="TNM perihilar cholangio";
var content_f4_11_4285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for perihilar cholangiocarcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2a",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades beyond the wall of the bile duct to surrounding adipose tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2b",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades adjacent hepatic parenchyma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades unilateral branches of the portal vein or hepatic artery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades main portal vein or its branches bilaterally; or the common hepatic artery; or the second-order biliary radicals bilaterally; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis (including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2a-b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       T1-3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0-1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4285=[""].join("\n");
var outline_f4_11_4285=null;
var title_f4_11_4286="Epiphrenic diverticulum Barium";
var content_f4_11_4286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epiphrenic diverticulum seen on barium swallow study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow study, performed in a patient with dysphagia and recurrent reflux, shows a large epiphrenic diverticulum (white arrow) which has arisen immediately above a stricture (black arrow) of the distal esophagus. This stricture was caused by chronic reflux esophagitis and the patient required an antireflux procedure, and resection of the stricture and diverticulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4286=[""].join("\n");
var outline_f4_11_4286=null;
var title_f4_11_4287="TEE LAA";
var content_f4_11_4287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/75036/teeltaap_conv.mp4?title=TEE+LAA\" style=\"width:324px;height:236px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial appendage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram show the left atrium (LA) and left atrial appendage (LAA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_11_4287=[""].join("\n");
var outline_f4_11_4287=null;
